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Abstract 
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor which has been 
implicated in the regulation of immune responses. Toxic ligands have been reported to exert 
immune-suppressive effects via AhR activation. Apart from these negative toxic effects of 
AhR ligands the pharmaceutical drug VAF347 shows that AhR ligands could be of potential 
therapeutic use. The compound provokes an inhibition of allergic lung inflammation and is 
able to suppress pancreatic islet allograft rejection in mice. It has been shown that these 
immune-suppressive functions are likely mediated by altered dendritic cell function. 
Therefore we investigated AhR protein levels in DC subsets and found that Langerhans cells 
(LCs) and monocyte-derived Dendritic Cells (moDCs) express the highest protein levels 
followed by interstitial DCs (intDCs) and monocyte-derived LCs (moLCs). Investigations on 
VAF347 treated LCs have previously shown that activated AhR diminishes LC differentiation 
potential and dampens the maturation process. With respect to the varying levels of AhR in 
DC subsets we here ask the question whether moLCs are equally influenced by AhR ligands 
VAF347 and FICZ. We could show that moLC generation was increased in the presence of 
AHR ligands and that these cells expressed lower levels of E-cadherin. The maturation 
process was only slightly decreased upon LPS treatment but left unchanged upon PGN 
activation. Therefore we conclude that LCs and moLCs generation is differentially influenced 
by AhR ligands and that the maturation capacity is only slightly affected depending on the 
activation stimulus. We were able to stain AhR in human skin LCs thereby proofing the 
existence of AhR in-vivo in human skin. Our data show that independent of activation stimuli 
AhR is constantly present in the nucleus. Furthermore we focus on the molecular role of AhR 
in mediating NiSO4-induced hypersensitivity reactions in LCs. Interestingly we could show 
that the activation of LCs and moLCs with the chemical sensitizer NiSO4, but not chemical 
irritant SDS, led to the activation of AhR. The same pattern could be found for RelB which 
plays an important role in regulating DC maturation in general. With regard to existing reports 
suggesting an interaction between AhR and RelB signaling, we ask the question whether 
AhR and RelB interplay in the specific hypersensitivity reaction induced by chemical 
sensitizers in LCs. We made use of the retroviral gene transduction system and analyzed the 
AhR/RelB target IL8 to address this question. We found that AhR still translocates to the 
nucleus upon NiSO4 activation although RelB was cytoplasmically sequestered by the 
p100ΔN construct. Interestingly we observed a tendency to an immediately increased IL8 
production and secretion. Therefore we hypothesize that AhR and RelB indeed interplay in 
the regulation of hypersensitivity reaction in means of preventing overreaction by controlling 
gene expression in the nucleus. 
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Zusammenfassung 
Der Aryl Hydrocarbon Rezeptor (AhR) ist ein Ligand-aktivierter Transkriptionsfaktor der im 
Immunsystem eine wichtige Rolle spielt. Toxische Liganden aktivieren AhR und führen 
dadurch zur Unterdrückung der Immunantwort. Die Immun-Suppression durch AhR hat aber 
auch potentiell therapeutische Anwendungsgebiete bei der Unterdrückung von Autoimmun-
Erkrankungen und Transplantat-Abstoßungen. Es wurde gezeigt, dass die immun-
suppressive Funktion von AhR größtenteils durch eine veränderte Funktion der dendritischen 
Zellen (DZs) zustande kommt. Aus diesem Grund haben wir uns gefragt wie die AhR Protein 
Levels in verschiedenen DZs sind und fanden heraus das Langerhans Zellen (LZs) und 
Monozyt-abgeleitete DZs (moDZs) die höchsten Protein Levels an AhR exprimieren, gefolgt 
von interstitiellen DZs (intDZs) und Monozyt-abgeleiteten LZs (moLZs). Untersuchungen von 
VAF347 generierten LZs haben gezeigt, dass die Aktivierung von AhR zu einer 
beeinträchtigten LZ-Differenzierung führen. Außerdem war das Reifungs-Potential von LZs 
verringert. Da unsere Ergebnisse bereits unterschiedliche AhR Levels in LZs und moLZs 
zeigten, haben wir uns die Frage gestellt, ob moLZs im gleichen Ausmaß durch AhR 
Liganden beeinflussbar sind. Wir konnten zeigen, dass AhR-Ligand-generierte moLZs ein 
höheres Potential zur Differenzierung haben und dass diese Zellen eine geringere E-
cadherin Expression aufweisen. Außerdem ist der Reifungsprozess der Zellen nur bei LPS 
Stimulation geringfügig verringert während PGN Stimulation keinen signifikanten Einfluss 
hat. Aus diesem Grund können wir schlussfolgern, dass die Differenzierung von LZs und 
moLZs unterschiedlich stark von AhR Liganden beeinflusst wird. Außerdem ist die Reifung 
der Zellen nur geringfügig beeinflusst wobei der Effekt vom Aktivierungsstimulus abhängt. 
Wir konnten AhR in LZs von humanen Hautschnitten färben und so zeigen, dass AhR, 
unabhängig vom Aktivierungsstatus konstitutiv im Kern lokalisiert ist. Interessanterweise 
wurde gezeigt, dass menschliche Haut mit endogenen AhR Liganden gesättigt ist, was die 
andauernde Aktivierungsstimulus-unabhängige AhR Aktivierung erklären könnte. Weiters 
haben wir untersucht ob in der Hypersensitivitätsreaktion auf NiSO4 in LZs ein potenzielles 
AhR/RelB Zusammenspiel stattfindet, da wir interessante Übereinstimmungen in AhR und 
RelB Aktivierung nach NiSO4 Stimulation festgestellt haben. Wir verwendeten ein retrovirales 
Infektionssystem um Veränderungen in der IL8 Produktion und Sekretion zu untersuchen. 
Dieses Gen wird in der Literatur bereits als potentielles Ziel von AhR/RelB Interaktionen 
beschrieben. Wir konnten zeigen, dass AhR unabhängig von RelB in den Kern transloziert 
und dass RelB Inhibierung zu einer verstärkten IL8 Produktion und Sekretion nach nur drei 
Stunden führt. Zusammenfassend können wir sagen, dass AhR und RelB tatsächlich 
zusammen wirken um die Hypersensitivitäts-Reaktion auf NiSO4 zu regulieren. Weiters 
konnten wir feststellen, dass dieser Mechanismus erst auf Ebene der Genregulation im 
Zellkern stattfindet. 
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Introduction 
 
1. Hematopoiesis 
Hematopoiesis defines the process of the sequential differentiation steps from hematopoietic 
stem cells towards multiple cell lineages which altogether build up the unique hematopoietic 
and immunologic system. During this stepwise differentiation process the initially multipotent 
hematopoietic stem cells gradually lose their differentiation potential and become restricted 
towards a lineage. Reya et al (Reya et al. 2001) established the bi-lineal model of the 
hematopoiesis which claims that the hematopoietic stem cell (HSC) (Morrison et al. 1995) 
first differentiates either into a common myeloid precursor (CMP) (Akashi et al. 2000) or into 
a common lymphoid precursor (CLP) (Kondo et al. 1997). After this first cell fate decision the 
CLPs can commit into three different cell lineages, namely B-cells, T-cells and NK-cells 
which form the lymphoid part of the immune system. The CMPs on the other hand lost their 
lymphoid potential and differentiate into either a megakaryocyte-erythro-progenitor (MEP) or 
a granulocyte-macrophage-progenitor (GMP). The terminally committed cell lineages of 
eosinophils, basophils, megacaryocytes and erythrocytes differentiate from the MEPs. 
Myeloid cell types like granulocytes, monocytes, macrophages and dendritic cells develop 
from GMPs (Figure 1). Later on scientist further identified a common dendritic progenitor 
(CDP) cell type in the bone marrow which either gives rise to the pre-DC progenitor or 
plasmacytoid DCs (del Hoyo et al. 2002). Pre-DC progenitors leave the bone marrow and 
migrate through the blood stream to the lymphoid organs where they further differentiate into 
tissue-specialized DC subsets (Liu et al. 2009). However, in the last years there have been 
reports that besides the CLP and CMP, there exists a third multipotent progenitor, namely 
the lymphoid-primed multipotent progenitor (LMPP) (Adolfsson et al. 2005; Lai and Kondo 
2006; Yoshida et al. 2006). In fact, this implies that the first decision in HSC differentiation is 
between megacaryocyte/erytho and myeloid/lymphoid cell fates and the 
granulocyte/macrophage lineage can arise from either LMPPs or GMPs (Luc et al. 2007). 
Most of the dendritic cells arise from the myeloid pathway, although CLP have recently been 
reported to have the potential to generate DCs (Akashi et al. 2000; Manz et al. 2001; Wu et 
al. 2001).  
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Hematopoiesis is tightly regulated not only by intrinsic factors such as transcriptional 
programs but also by extrinsic signals from the microenvironment. Hematopoietic cells and 
immune cells mainly communicate via cytokines (interleukins, chemokines, and interferons) 
and are partly characterized by their production and responsiveness to these low molecular 
weight proteins which are part of a sophisticated network of cellular signaling. For example 
the DC progenitors are characterized by their ability to produce and respond to Fms-related 
tyrosine kinase 3 ligand (FLT3L) (Schmid et al. 2010). 
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2. Immune system: 
The immune system is constituted by specialized cells of the hematopoietic system and is 
able to protect the organism from invading microbes, viruses, macromolecules, proteins, 
polysaccharides and small chemicals which are potentially harmful. The immune response 
itself is produced by two parts of the immune system, namely the innate immune system 
(early response) and the adaptive immune system (later responses). The innate immune 
response only recognizes structures shared by groups of related microbes, has no memory 
and always reacts in the same way. It is comprised of physical and biochemical barriers such 
as epithelia and antimicrobial substances. In addition to this the proteins of the peripheral 
blood complement system and phagocytic cells like macrophages or dendritic cells exert 
immediate protective functions within the first 12 hours of an infectious encounter thereby 
limiting the expansion of the infection and activating the adaptive immune system which 
targets the infection more specifically via antigen recognition. The main players of the 
adaptive immunity are the lymphocytes. On the one hand the humoral immunity mediated by 
B-cells which blocks infections by producing antibodies directed against specific extracellular 
antigens and subsequently leading to the elimination of the infection. On the other hand the 
cell-mediated immunity by T-cells which reacts to intracellular pathogens. CD8 positive T-
cells exert the cytotoxic killing response whereas the CD4 positive T-cells can differentiate 
into 4 T helper subsets with divergent functions. Th1 cells act against intracellular pathogens 
and are involved in allergy induction. Th2 cells play a crucial role in defense against 
extracellular pathogens and induction of allergy and act as T effector-cells. Th17 cells are 
implicated in autoimmunity and antimicrobial mechanisms against extracellular parasites and 
fungi. T-regs control the induction of tolerance and immune responses and function as 
important lymphocyte homeostasis. For T-cells it is essential to interact with other antigen-
presenting-cells (APCs) such as macrophages or dendritic cells which process and present 
the antigen on major histocompatibility complexes (MHC) class I and II on their cell surface. 
Activated T-cells then initiate the immune response by either directly killing infected cells 
(MHC class I presentation of cytosolic antigens to CD8+ T lymphocytes) or acting as T helper 
cells to induce other mechanisms of clearance or tolerance (MHC class II presentation of 
vesicular antigens to CD4+ T-lymphocytes). The defining characteristics of the later immune 
response are the specificity against antigens enabled by clonal selection of T-cell clones with 
the highest specificity for antigens. In addition to this T cells are unique in their immense 
diversity of antigen recognition which is possible because of the somatic recombination of 
receptor gene segments. Furthermore the adaptive immune system has the ability to 
memorize antigens and elicit more effective immune responses to the same antigen. 
(compare (Abbas et al. 2007) 
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2.1. Dendritic cell subsets: 
Dendritic cells are distributed in multiple organs throughout the body and are professional 
antigen-presenting cells. Their function is crucial for the induction of the adaptive immune 
response. Research of the last decades showed that dendritic cells are composed of a 
heterogeneous pool of cells with different surface marker expression, function and origin. 
First of all DCs are divided into conventional DCs and non-conventional DCs (Shortman and 
Naik 2007). Conventional DCs differentiate from CDPs and pre-DC precursors and act as 
normal antigen capturing and processing cells. On the other hand we have the non-
conventional class of DCs which either originate from a different source than CDP or pre-DC 
precursors or have different functions than the conventional DCs. All DC subsets which 
differentiate from monocytes in steady-state or inflammation are counted to the non-
conventional class of DCs. They are found in peripheral tissues such as lung, liver, skin, 
intestine or kidneys where they function as classical antigen presenting cells (APCs) and 
subsequently migrate to the draining lymph nodes to initiate the adaptive immune response. 
Furthermore the plasmacytoid DCs (pDCs), found in lymphoid or non-lymphoid organs, are 
also classified as non-conventional subsets because their function differs markedly from 
common DCs. They secret high amounts of type I interferon upon viral infection (Guiducci et 
al. 2008), continuously present endogenous viral antigen even in the activated state (Young 
et al. 2008) and they play an important role in the maturation of activated B-cells towards 
antibody-secreting plasma cells (Jego et al. 2003). The conventional class of DCs is further 
divided into migratory and lymphoid-tissue resident DC subsets. The migratory DC subsets 
are located in multiple organs such as intestine, lung, liver, kidney or the skin where they 
monitor incoming pathogens and subsequently process them to present them in the draining 
lymph nodes. The lymphoid-tissue resident DCs on the contrary are found in lymphoid 
organs such as the thymus, spleen or lymph nodes and lack any migratory capacities. They 
are differentiated from pre-DCs and are further classified according to their surface marker 
expression of CD4 and CD8 (Naik et al. 2006). There are three types of lymphoid-resident 
DCs, namely the CD8+CD4-, CD8-CD4- and the CD8-CD4+ cells. CD8+CD4- DCs play a 
crucial role in viral immunity because they present viral antigen via MHC class I and secret 
high amounts of interferon-α in response to viral infections and intracellular pathogens which 
increases the cyto-toxicity of NK-cells and T-cells (Hochrein et al. 2001). CD8-CD4- double 
negative DCs secret high amounts of interferon-γ and initiate a CD8+ cyto-toxic T-cell 
response (McLellan et al. 2002). CD8-CD4+ DCs are predominately described as immune-
tolerating and autoimmune-dampening cells which are potent inducers of CD4+ T-cell 
responses (Dudziak et al. 2007; Legge et al. 2002). Above mentioned classifications of DC 
subsets are also reviewed in (Kushwah and Hu 2011; Liu and Nussenzweig 2010; Merad 
and Manz 2009) and are illustrated in figure 2. 
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2.2. Dendritic cell function 
The basic characteristic of immature dendritic cells (DCs) is the very potent antigen 
processing function which allows them to take up and thus monitor incoming antigens for 
their pathogenic potential. Being the link between the innate and the adaptive immune 
system these specialized cells are able to decide whether to tolerate a certain antigen or 
induce a pro-inflammatory immune response. Upon the encounter of an antigen DCs 
undergo the so-called maturation process, in which they lose the antigen processing capacity 
and gradually gain antigen presenting and T-cell stimulatory functions. DCs are specialized 
in taking up and processing antigens to subsequently present antigen peptides on the cell 
surface via MHC class I and II molecules. Activated DCs initiate the expression of the 
chemokine receptor CCR7 and are thereafter capable of responding to chemokines which 
lead to the migration of the antigen-loaded cells to the adjacent draining lymph nodes (Saeki 
et al. 1999; Stoitzner et al. 2002). In these secondary lymphoid organs DCs migrate to the T-
cell rich zone where they present the processed antigen to T-cells. For the proper interaction 
with T-cells in the lymph nodes DCs need to undergo further phenotypical changes while the 
maturation process. They gradually increase the expression of co-stimulatory molecules like 
CD86, CD80 and CD40 which are necessary for T-cell activation and increase the 
expression of accessory molecules like CD83 and antigen-presenting molecules like MHC 
class I and II (eg. HLADR). Furthermore, activated DCs initiate the production of specific, 
Introduction 
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antigen-dependent cytokines which then govern the differentiation of T-cells towards a 
particular phenotype (T helper 1, 2 and 17 and Treg) and thereby shape the upcoming 
immune response (de Jong et al. 2005). In addition to this DCs are also essential for the 
maintenance of self-tolerance. Upon the encounter of self-antigens DCs are not properly 
activated in means of a dampened up-regulation of co-stimulatory molecules and pro-
inflammatory cytokines. These cells are able to induce apoptosis or anergy of T-cells or the 
differentiation of regulatory T-cells (Steinman et al. 2003). 
 
2.3. Langerhans cells: 
The skin is the biggest organ of the human body and is constantly exposed to environmental 
particles such as chemicals or microorganisms. Langerhans cells are the dendritic cells of 
the epidermis and form a regular network (Romani et al. 2003). As protective guards they 
reside in the skin for long time periods (Merad et al. 2002). Nowadays scientists mostly 
believe, that hematopoietic progenitors populate the skin during embryonic development 
which then give rise to LCs during life (Ginhoux and Merad 2010). New results from mice 
studies suggest that LCs, populating the healthy adult skin have a dual origin. The majority of 
LCs originates from fetal liver monocytes which differentiate from myeloid progenitors in the 
liver before they migrate to the dermis and further differentiate into LC precursors. Apart from 
this the authors also found that yolk sac primitive macrophages contribute to LCs by 
migrating through the blood stream to the developing skin of the embryo to give rise to 
myeloid precursors. Although it is speculative the authors hypothesize that LC precursors are 
present in the skin before the hematopoiesis starts in the bone marrow while embryogenesis 
(Hoeffel et al. 2012). It is believed that LCs can repopulate themselves by self-renewal under 
steady state conditions (Chorro et al. 2009). However, Ginhoux et al could show that 
inflammatory conditions enable peripheral blood monocytes to differentiate into LCs 
(Ginhoux et al. 2006). Recently there have been two groups indicating that CD14 positive 
cells either from the blood or dermal resident cells can differentiate into LCs and therefore 
constitute possible LC self-renewal mechanisms (Larregina et al. 2001; Schaerli et al. 2005). 
Langerhans cells are phenotypically characterized by the expression of the dendritic surface 
marker CD1a (Fithian et al. 1981) and the mannose-specific C-type lectin Langerin (CD207) 
(Valladeau et al. 2000). In addition to this they express E-cadherin to interact with the 
surrounding keratinocytes (Tang et al. 1993). It has been shown that this molecule inhibits 
uncontrolled maturation of LCs (Riedl et al. 2000). However, E-cadherin is subsequently 
down-regulated upon maturation stimuli to ensure DC migration towards the adjacent 
draining lymph node and therefore the initiation of an immune response (Schwarzenberger 
and Udey 1996). Once LCs arrive in the draining lymph nodes they can either present the 
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antigen directly to T-cells or hand over the antigen to resident CD8+ lymphoid DCs which in 
turn cross-present it to CD4+ and CD8+ T-cells (Allan et al. 2006; Carbone et al. 2004; 
Stoitzner et al. 2006). Monocytic markers like CD11b and CD14 are not present on LCs. 
Furthermore LCs have special intracellular rod- or rocket like structures called Birbeck 
granules (Birbeck et al. 1961) which are characteristic for this cell type. 
 
 
2.4. Cytokines required for DC differentiation: 
In the process of identifying a common precursor for monocytes and dendritic cells, research 
on peripheral blood mononuclear cells was pioneering. Kasinrerk et al. (Kasinrerk et al. 
1993) found that the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) is 
a substantial requirement for the induction of the dendritic cell marker CD1 expression. 
Today we use GM-CSF and additional IL4 for the efficient in-vitro generation of DCs from 
peripheral blood monocytes, because it was shown, that IL4 addition leads to a decrease of 
monocytic marker CD14 and enhances the accessory functions of DCs (Romani et al. 1994; 
Ruppert et al. 1993; Sallusto and Lanzavecchia 1994). Interestingly in 2003 Mallah et al. 
reported of a GM-CSF independent generation model of LC like cells from CD34 positive 
cells (Mollah et al. 2003). However, with ongoing research progress it was then possible to 
isolate CD34 positive hematopoietic stem cells (HSC) from the cord blood. Researches then 
started to elucidate the culture conditions to generate committed cell lines. Caux et al. 
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cultured CD34 positive HSCs in serum supplemented medium and found that the cells gain 
DC characteristics when differentiated in the presence of GM-CSF and tumor necrosis factor 
α (TNFα) (Caux et al. 1992). About 20% of the CD1a positive cells were Birbeck granule 
positive LCs. The addition of IL4 to this cytokine mix increased the CD1a positive cell fraction 
(Rosenzwajg et al. 1996; Strunk et al. 1996) and the supplementation of stem cell factor 
(SCF) further enhanced the DC yield (Szabolcs et al. 1995; Young et al. 1995). However, the 
breakthrough in elucidating the cytokine requirements for proper LC in-vitro generation came 
with the identification of TGF-β1 as a crucial factor for LC differentiation (Strobl et al. 1996). 
This research group tried to establish a serum-free LC generation model to make future 
medical application more applicable. They differentiated the cells in serum-free medium with 
GM-CSF, TNFα, SCF and TGF-β1 and observed a significant increase in CD1a positive cells 
compared to the cells without TGF-β1 treatment. In addition to this cells formed the typical 
DC clusters and around 20% of the TGF-β1 cultured cells showed birbeck granules and a 
positive staining for Langerin. It was further shown, that the promoting effect of TGF-β1 in the 
in-vitro generation of dendritic cells is achieved by inhibiting apoptosis of progenitor cells 
(Riedl et al. 1997). The results of this group are in line with the observation that TGF-β1 
knock-out mice selectively lack Langerhans cells in the skin while still generating other 
dendritic cell types and monocytes in the peripheral blood (Borkowski et al. 1996). Ten years 
later it has been discovered that the TGF-β1, produced by LCs itself, is crucial for LC 
development and survival in an autocrine/paracrine way (Kaplan et al. 2007). Not only LCs 
produce their own TGF-β1 but also epidermal keratinocytes secret this cytokine. The serum-
free LC generation model with GM-CSF, TNFα, SCF and TGF-β1 offered an ideal 
experimental set up to find out that the cytokine fms-related tyrosin kinase 3 ligand (Flt3L), 
which was already known to act as growth factor for hematopoietic progenitors (Lyman et al. 
1994; Maraskovsky et al. 1996), specifically promoted the expansion of a common progenitor 
of monocytes and LCs, because the percentage of CD1a positive cells with molecular 
features of LCs was significantly increased while the ratio between monocytic and dendritic 
cells in the culture system was unchanged (Strobl et al. 1997). Above mentioned cytokine 
findings are also reviewed in (Strobl and Knapp 1999; Strobl et al. 1998).  
It is quite interesting that TGF-β1 inhibits the maturation of immature LCs in murine bone 
marrow derived dendritic cells (Yamaguchi et al. 1997). One can speculate that this indeed is 
a clever move of nature concerning the fact that epidermal LCs are constantly exposed to 
environmental particles and need to have a sophisticated mechanisms to establish tolerance 
and control immune reactions. Apart from TGF-β1-maturation suppressing function, ongoing 
research further sheds light on the tolerance establishment in DCs. One interesting 
candidate is the β-catenin/Wnt signaling pathway which is activated via E-cadherin 
disruption. Upon the release of E-cadherin-sequestered β-catenin due to cell-cell junction 
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disruption or E-cadherin downregulation upon antigen encounter, β-catenin translocates to 
the nucleus where it binds to T cell factor/lymphoid enhancer factor (TCF/LEF) and turns on 
the expression of immune tolerance inducing genes (IL10, TGF-β1) (Fu and Jiang 2010; 
Manicassamy et al. 2010; Van den Bossche et al. 2012). This leads to the hypothesis that 
LCs continuously induce tolerance by TGF-β1 and β-catenin signaling and are only able to 
induce immune responses when pathogen recognition receptor signaling efficiently 
overwrites tolerogenic signals with inflammatory danger signals.  
 
2.5. Transcription factors directing DC differentiation: 
As mentioned above, GM-CSF is an essential cytokine in DC differentiation by acting as 
growth factor for common precursor cells. GM-CSF signaling on the one hand activates 
signal transducer and activator of transcription (STAT) 5, which represses the transcription 
factor interferon regulatory factor (IRF) 8 important for the differentiation of plasmacytoid 
dendritic cells. On the other hand GM-CSF signaling activates STAT3, which induces the 
important DC differentiation factor IRF4 (Schiavoni et al. 2002). FLT3L cytokine is essential 
for DC differentiation and it mediates its effects, amongst others, through the hematopoietic 
master transcription factor PU.1. This transcription factor is expressed in all DC subsets and 
CDP progenitors and is required for myeloid and lymphoid DC differentiation in an instructive 
and concentration-dependent manner (Anderson et al. 2000; Carotta et al. 2010; Guerriero et 
al. 2000). Another important transcription factor in DC differentiation is RelB, the NFκB family 
member of the non-canonical pathway. Platzer et al found that RelB over-expression 
promotes the generation of monocytic intermediates which are the precursors of 
CD11b+CD1a+ interstitial DCs while not affecting LC differentiation (Platzer et al. 2004). The 
transcription factor Ikaros is especially important for the differentiation of DC subsets from 
common lymphoid progenitors (Wu et al. 1997). The transcription factor growth factor 
independent 1 (Gfi1) in contrast seems to function as a transcriptional repressor because the 
Gfi knock-out mice show an increased number of LCs, whereas lymphoid resident DCs were 
reduced (Hock et al. 2003). Apart from this it was also shown that this transcription factor 
seems to be important in the DC versus macrophage decision (Rathinam et al. 2005). As 
TGF-β1 is a crucial cytokine in LC differentiation it is not astonishing that the main 
transcription factors in LC development are activated by its signaling. One interesting 
candidate is the TGF-β1 responsive transcription factor inhibitor of differentiation 2 (Id2). Id2 
knockout mice lack LCs (Hacker et al. 2003) whereas the over-expression of Id2 in 
hematopoietic stem cells leads to an inhibition in plasmacytoid differentiation (Spits et al. 
2000). Heinz et al. reported that TGF-β1 induces PU.1 and Id2 up-regulation in CD34 derived 
LCs and that PU.1 strongly promotes LC differentiation while Id2 suppresses monocyte 
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differentiation (Heinz et al. 2006). Runt related transcription factor 3 (Runx3) also counts to 
the TGF-β1 signaling inducible transcription factors involved in LC differentiation as Runx3 
knock-out mice completely lack LCs (Fainaru et al. 2004). Vitamin D 3 receptor (VDR) has 
also been described to be induced by TGF-β1 and is specifically induced while LC 
differentiation. GATA1 on the other hand is induced by IL4 in monocyte-derived dendritic cell 
differentiation. Göbel et al showed that GATA1 functions as a repressor of VDR (Gobel et al. 
2009). To sum up the downstream targets of TGF-β1 signaling: Id2, Runx3 and Pu.1 are 
strictly obligatory for LC differentiation. Above described transcription factors are in part 
reviewed in (Merad and Manz 2009; Zenke and Hieronymus 2006). 
 
2.6. Signal transduction pathways in DC maturation 
DCs express a cell-type specific repertoire of pattern recognition receptors (PRRs) on their 
surface. The family of PRRs comprises four different classes, namely the nucleotide oligo 
dimerization domain (NOD)-like receptors, retinoid acid receptor inducible gene I (RIG-I)-like 
receptors, C-type lectin receptors (CLRs) and the toll-like receptors (TLRs) which enable 
them to recognize pathogen associated molecular patterns (PAMPs) of bacteria, viruses or 
fungi in their environment. Each DC subset expresses a unique repertoire of PRRs which 
leads to a specific and diverging response towards extracellular stimuli (Netea et al. 2005). 
Human dendritic cells express 10 different TLRs which can further be divided into 
extracellular TLRs (TLR1, 2, 4, 5, and 6) which recognize exterior compounds of bacteria 
and fungi such as cell wall components. Intracellular TLRs (TLR3, 7, 8 and 9) recognize 
nucleoside-containing structures like RNA or un-methylated DNA from bacteria and viruses.  
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Table 1:Toll-like receptor signaling in immune responses 
Adapted from Kumar et al. 2009 
receptor location ligand adapter 
molecule 
signaling 
TLR1/2 PM Triacyl lipopeptides (bacteria 
and mycobacteria) 
MyD88 and 
TIRAP 
NFκB 
TLR2 PM PGN (gram+ bacteria), LAM 
(Mycobacteria), hemagglutinin 
(measles virus), 
phospholipomannan (Candida), 
glycosylphosphophatidyl 
inositol mucin (Trypanosoma) 
MyD88 and 
TIRAP 
NFκB 
TLR3 Endosome ssRNA virus (WNV), dsRNA 
virus (Reovirus), RSV and 
MCMV 
TRIF NFκB and 
IRF3/7 
TLR4 PM LPS (gram- bacteria), mannan 
(candida), 
glycoinositolphospholipids 
(Trypanosoma), envelope 
proteins (RSV and MMTV) 
MyD88, TIRAP, 
TRAM and 
TRIF 
NFκB and 
IRF3/7 
TLR5 PM Flagellin (flagellated bacteria) MyD88 NFκB 
TLR6/2 PM Diacyl lipopeptides 
(Mycoplasma), LTA 
(Streptococcus), Zymosan 
(Saccharomyces) 
MyD88 and 
TIRAP 
NFκB 
TLR7  Endosome ssRNA viruses (VSV, Influenza 
virus) 
MyD88 NFκB and IRF7 
TLR8 Endosome ssRNA from RNA viruses MyD88 NFκB and IRF7 
TLR9 Endosome dsDNA viruses (HSV, MCMV), 
CpG motifs from bacteria and 
viruses, hemozoin 
(Plasmodium) 
MyD88 NFκB and IRF7 
PM = Plasma membrane, LAM = Lipoarabinomannan, WNV = West Nile virus, RSV = Respiratory syncytial virus, MCMV = 
Murine cytomegalovirus, MMTV = Mouse mammary tumor virus, LTA = Lipoteichoic acid, VSV = Vesicular stomatitis virus, HSV 
= Herpes simplex virus, CpG = Cytidine-phosphate-guanosine. 
 
In general all TLRs use the adapter molecule myeloid differentiation primary-response 
protein 88 (MyD88) with the exception of TLR3 and 4. TLR3 instead engages with the TIR-
domain-containing adapter-inducing interferon-β (TRIF) molecule whereas TLR4 can use 
both adapter molecules (Akira and Takeda 2004). In general TLR ligand encounter leads to 
the dimerization of TLRs and subsequent recruitment of adaptor molecules. MyD88 then 
activates IRAK1/4 which further induces TRAF6. Together with TAK1, TAB1 and TAB2, 
TRAF6 then activates the NFκB and MAP kinase signaling pathways. TLRs predominantly 
exert their functions through the activation of NFκB and IRF signaling which ultimately leads 
to the induction of pro-inflammatory cytokines, type I interferons, induction of co-stimulatory 
molecules and the morphological changes towards a migratory phenotype. With the 
exceptions of TLR3 and TLR4 MyD88 is strictly required for DC maturation. TLR signaling of 
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DCs is also reviewed in (Akira and Takeda 2004; Kawai and Akira 2010; Kumar et al. 2009) 
LPS stimulation via the TLR4 is special because it needs a LPS-binding protein (MS2) which 
dimerizes with the co-receptor CD14 upon LPS binding. The activated TLR4 complex is then 
able to induce two different responses. The early response signals via MyD88 and induces 
NFκB whereas the late response is MyD88-independent but needs the TRIF/TRAM signaling 
cascade to activate NFκB and IRFs (Palsson-McDermott and O'Neill 2004). 
 
 
 
2.7. MAP kinase and NFκB signaling in DC maturation: 
A lot of immune functions are mediated via the NFκB signaling cascade, also because it is an 
ideal platform to interlink signals from innate and adaptive immunity. Knock-out mice studies 
of NFκB showed that the function of antigen-presenting cells and lymphocytes are highly 
regulated by this transcription factor family. NFκB transcription factors always bind to κB 
DNA sequences in promoters and enhancers of target genes as NFκB/Rel heterodimers or 
p50 and p52 homodimers. They can exert positive and negative effects on transcription and 
play a role in multiple cell types. The NFκB transcription factor family is comprised of 5 
proteins which characteristically harbor an N-terminal Rel domain for rel protein interaction. 
RelA (p65), RelB and c-Rel additionally possess C-terminal transactivation domains (TADs) 
which render them capable of initiating transcription. NFκB1 (p50 from p105) and NFκB2 
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(p52 from p100) are kept in the cytoplasm in an inactive precursor form, namely p105 or 
p100 respectively. These NFκB1 and 2 proteins possess an inhibitory domain which keeps 
them in the cytoplasm. While the p105 precursor is processed spontaneously the p100 
precursor only gets processed upon activation. However the inhibitory domains are 
phosphorylated, ubiquitinylated and processed in a proteosome-dependent way, resulting in 
the active p50 or p52 proteins displaying a nuclear localization sequence (NLS) necessary 
for nuclear translocation of the NFκB/Rel hetero- or homodimers. Moreover the NFκB 
signaling cascade consists of 5 different inhibitory proteins called inhibitor of κB (IκBs), 
namely IκBα, β, ε, γ and Bcl-3. The function of these proteins is to sequester the NFκB/Rel 
heterodimers or homodimers in the cytoplasm and inhibit signaling. Only upon activation 
signals the Inhibior of κB kinase complex (IKK) is activated. This in turn leads to the 
phosphorylation and ubiquinitylation of the inhibitory IκB inducing the proteosomal 
degradation. The transcriptionally active dimmers are now able to translocate into the 
nucleus. Generally the NFκB signaling pathway is divided into the cananonical (classical) 
pathway and the non-canonical (alternative) pathway. The canonical pathway, including RelA 
dimers with p50 or c-Rel, is activated by ligand-activated cytokine receptors such as TNFα- 
or IL-1 receptors, activated PRRs such as toll-like receptors or antigen-receptors such as the 
T-cell receptor (TCR). The RelA/c-Rel heterodimer forms a complex with IκBα whereas the 
C-terminus of the p105 precursor first has to be degraded to the p50 protein which then 
forms heterodimers with RelA. This p105-degradation process occurs spontaneously and the 
thereby produced p50 proteins can either heterodimerize with RelA or c-Rel or form 
homodimers. The p50 heterodimer are also inhibited from nuclear translocation by the 
association of an IκB inhibitory protein. Signal propagation occurs via IKKβ (IKK2) which 
forms a complex with IKKα (IKK1) and the regulatory protein IKKγ (NEMO). This activated 
IKK complex then phosphorylates the IκB protein which ultimately leads to its ubiquinitylation 
and proteosomal degradation. The active p50 or RelA/c-Rel heterodimers then translocated 
to the nucleus where they initiate transcriptional changes. The non-canonical or so-called 
alternative NFκB pathway on the other hand signals through RelB/p52 heterodimers. TNF 
cytokine family and ligands such as CD40L, BAFF and lymphotoxinβ induce the alternative 
signaling pathway by activating the NFκB-inducing kinase (NIK). NIK subsequently 
phosphorylates IKKα which is essential for the alternative pathway whereas NEMO is not 
needed in this process (Sun 2011). P100 precursor finally gets phosphorylated and 
ubiquitinylated leading to the proteosomal degradation of the C-terminus generating the p52 
protein with a nuclear localization sequence. P52 exists in complex with RelB and forms the 
transcriptionally active heterodimer which performs transcriptional changes after nuclear 
translocation and DNA binding to κB sites. It has to be said that p50 and p52 homodimers 
can be formed and mostly exert repressive effects on DNA sequences by competing with 
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transcriptionally active heterodimers (Zhong et al. 2002). However, whether the homodimers 
repress or activate transcription is also determined by special IκB association. When 
considering the ability of IKKα and IKKβ to crosstalk with multiple signaling cascades (p53, 
MAP kinases and IRF pathways), it becomes obvious why the NFκB signal transduction 
cascade plays such an important role in integrating signals from innate and adaptive 
immunity to exert an adequate immune response. (reviewed in (Ghosh and Hayden 2008; 
Hayden and Ghosh 2012; Hayden et al. 2006)  
It is important to mention that nuclear RelB expression in DCs serves as hallmark for 
maturation as immature DCs show no RelB in the nucleus whereas mature DCs in T-cell 
areas of lymph nodes and tonsils are highly positive for nuclear RelB (Clark et al. 1999; Pettit 
et al. 1997). Overall the classical NFκB signaling cascade is immediately turned on after 
danger signals and exerts pro-inflammatory responses. The alternative RelB pathway on the 
contrary serves as immune-regulatory pathway as LCs deficient in RelB signaling show 
hyper-maturation (Jorgl et al. 2007; Saccani et al. 2001). These results are in line with the 
hyper-inflammatory phenotype of RelB knock-out mice (Weih et al. 1995). Additionally in the 
last years there have been reports claiming that RelB and RelA NFκB members are also able 
to interact with signaling molecules beyond the NFκB family, namely the aryl hydrocarbon 
receptor (AhR) (Kim et al. 2000; Ruby et al. 2002; Vogel et al. 2007). This topic will be 
discussed in chapter 3.5. in more detail. 
In our experiments dedicated to investigate the interaction between RelB and AhR we make 
use of a p100ΔN construct, which lacks C-terminal ankyrin repeats essentially needed for 
subsequent proteosomal degradation of the p100 precursor to the active p52 protein. It has 
been described that this truncated form of the p100 precursor inhibits nuclear translocation of 
the RelB/p52 heterodimer (Solan et al. 2002). Our lab has already worked with this construct 
and found that inhibiton of the alternative RelB signaling cascade inhibits intDC development 
by promoting a monocytic intermediate (Platzer et al. 2004). Furthermore Jörgl et al. showed 
that conditionally active LC maturation is counter regulated by RelB. RelB inhibition led to LC 
hyper maturation (Jorgl et al. 2007). 
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Mitogen activated protein kinase (MAPK) signaling cascades play an important role in the 
generation and regulation of immune responses. This class of signal transduction depends 
on sequential phosphorylation steps on and from kinases which ultimately phosphorylate 
transcription factors which in turn exert immunological responses via transcriptional 
alterations. As a first step extracellular signals are received via receptors or simply diffuse 
into the cell. The spectrum is wide and ranges from hormones, growth factors, antigenic 
stimuli, cytokines, interferons and oxidative stress to small chemicals. These priming signals 
activate MAP kinase kinase kinase (MAPKKK) proteins by phosphorylation. This activation 
signal is then transmitted to the next instance, namely the MAP kinase kinases (MAPKKs) 
These enzymes finally phosphorylate 3 classes of MAP kinases (MAPKs), namely the c-Jun 
N-terminal kinse (JNK), extracellular-signal regulated kinase (ERK) and p38 MAPK. 
Activated MAPKs then activate a wide range of transcription factors. These transcriptional 
program alterations finally enable the cell to adequately respond to the signals received from 
the environment. Candidates are signal transducer and activator of transcription (STATs), 
AP-1 (c-jun, c-Fos and activation of transcription (ATF), NFκB1, E twenty six like transcription 
factor (ELK1), T-cell factor (TCF) and cAMP responsive-element binding protein (CREB3). 
While the ERK pathway has distinct MAPKKKs and MAPKK which specifically activate the 
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ERK MAPK, p38 and JNK signaling cascades are not easily distinguishable. Already on the 
MAPKKK level they share some activation proteins such as TAK1, ASK1, MLK3 and MEKK1, 
3 and 4 (Blank et al. 1996; Karandikar et al. 2000; Waetzig and Herdegen 2005). In addition 
it was shown that MAP kinase kinase enzyme MKK4 has the capacity to activate both 
MAPKs JNK and p38 while other MAPKKs like MKK7 (JNK) and MKK3/6 (p38) are specific 
for either cascade (Ganiatsas et al. 1998). The MAPK-ERK pathway is generally known as 
survival pathway mediating proliferation and differentiation whereas the MAPK JNK is 
implicated in cellular signaling, immune responses and apoptosis. The four isoforms of p38 
(α, β, γ, δ) mostly respond to stress signals and induce inflammatory or apoptotic responses 
and are implicated in cell cycle regulation. (reviewed in (Cargnello and Roux 2011; Junttila et 
al. 2008; Puga et al. 2009). MAP kinase phosphatases (MKP) add another level of 
complexity to the MAPK signaling as they are able to inhibit kinase activity of more than one 
pathway (Junttila et al. 2008).  
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For our experiments we are using special inhibitors to elucidate the role of MAPK and NFκB 
signaling in the activation of LCs and subsequent AhR nuclear translocation. SB203580 
inhibitor specifically inhibits p38α, p38β and p38β MAPK catalytic activity by blocking the 
ATP binding pocket rather than inhibiting its phosphorylation (Cuenda et al. 1995; Kumar et 
al. 1999). Other MAPK pathways are unharmed by this inhibitor. SB216763 inhibits the 
GSK3α and β kinase activity. These enzymes usually phosphorylate β-catenin and target it 
for degradation thereby inhibiting active β-catenin/Wnt signling. Besides multiple other 
actions in various signaling pathways SB216763 inhibits GSK3β and turns on the β-
catenin/Wnt signaling (Coghlan et al. 2000). SP600125 inhibitor specifically abrogates the 
phosphorylation of JNK MAPK therefore inhibiting this signaling cascade (Bennett et al. 
2001). SN-50 inhibitor retains the NFκB family member p50 in the cytoplasm by sequestering 
the nuclear translocation sequence and anchoring it to the plasma membrane via a 
hydrophobic region (Lin et al. 1995). 
 
2.8. Contact hypersensitivity: 
Haptens are low molecular weight chemicals which cause a contact hypersensitivity reaction 
when applied to the skin. This biological response leads to contact dermatitis which can be 
classified into irritant and allergic dermatitis. Irritant contact dermatitis on the one hand is a 
classical inflammatory reaction caused by the toxic character of certain haptens. On the 
other hand the allergic contact hypersensitivity is an antigen-specific immune response of the 
adaptive immune system towards haptens. In our studies we use the chemical irritant sodium 
dodeyl sulfate (SDS) as inducer of irritant contact hypersensitivity reactions and the chemical 
sensitizer nickel sulphate (NiSO4) as inducer of allergic hypersensitivity reactions. The 
allergic contact hypersensitivity is characterized by the sensitization and elicitation phase 
each comprised of 3 sequential steps. The sensitization phase is initiated by antigen invasion 
and activation of langerhans cells which subsequently start the maturation process and 
migrate to the draining lymph nodes where they finally present the processed antigen to CD4 
and CD8 positive T-cells. The following elicitation phase starts with the migration of activated 
T-cells to the skin where LCs, T-cells and keratinocytes crosstalk via cytokines and 
interferons. Finally keratinocytes are targeted by inflammatory responses elicited by T-cells 
triggering apoptosis and thereby dermatitis symptoms. It is important to mention that the 
research team around Setsuya Aiba could show in multiple studies that only chemical 
sensitizers inducing allergic hypersensitivity lead to the maturation process of DC subsets in 
vivo and in vitro while chemical irritants function via different pathways (reviewed in (Sasaki 
and Aiba 2007). Concerning the investigation of signaling transduction leading to DC 
maturation upon hapten encounter there are multiple studies from various labs most of them 
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outlining the involvement of p38 MAPK among others. First it was shown that strong haptens 
induce phosphotyrosines in moDCs (Kuhn et al. 1998), later on it was shown that p38 MAPK 
activation is involved in the maturation process upon treatment with chemical sensitizers of in 
vitro moDCs (Aiba et al. 2003; Arrighi et al. 2001). Boislève et al. showed that p38 MAPK 
induces CCR7 expression upon NiSO4 treatment which is essential for the induction of a 
migratory phenotype of mature DCs (Boisleve et al. 2004). Miyazama et al implicated p38 
and ERK MAPK activation in the NiSO4-treated THP-1 cell line. P38 inhibition led to a 
decrease in co-stimulatory molecule expression (Miyazawa et al. 2007). There are 
convincing studies linking the p38 MAPK activation to an imbalance in the redox system in 
the cell detected by a recued GSH/GSSG ratio (Sasaki and Aiba 2007). DCs activate IL-12 
production upon NiSO4 activation by a mechanism that involves STAT1 phosphorylation and 
further IRF1 induction by redox stress. This mechanism further proves the activation of 
MAPKs by intracellular redox imbalance caused by haptens (Antonios et al. 2010). However 
knockout mice selectively lacking LCs showed controversial results from unchanged to 
reduced and amplified contact hypersensitivity (Bennett et al. 2005; Kaplan et al. 2005; 
Kissenpfennig et al. 2005). These findings suggest that LCs are not the first responders to 
haptens in contact hypersensitivity. In fact it was proposed that CD14 positive dermal DCs 
play an important role. Kissenpfennig et al. made the important discovery that upon hapten 
skin painting of mice dermal DCs were the first cells present in the lymph node after only 24 
hours whereas LCs arrived 2-4 days later. Additionally these two DC subsets migrated to 
distinct areas in the lymph node (Kissenpfennig et al. 2005). Above mentioned contact 
dermatitis findings were also partially reviewed in (Sasaki and Aiba 2007). 
There has been an interesting paper by Jux et al. showing that LC maturation and contact 
hypersensitivity are impaired in Aryl hydrocarbon receptor-null mice. It has also been shown 
that NiSO4 but not DNCB treatment of human DCs triggers RelA activation which in turn is 
important for the maturation process as the inhibition of nuclear RelA impaired this process. 
Interestingly RelA activation is independent of the p38 MAPK pathway which is also induced 
by NiSO4 treatment (Ade et al. 2007). With regard to our interest in aryl hydrocarbon receptor 
(AhR) function in LCs we investigate AhR levels in human skin upon the application of 
contact irritant (SDS) and contact sensitizer (NiSO4). We found interesting signaling analogy 
between AhR and RelB and further know that RelB plays an important role in limiting immune 
responses (Jorgl et al. 2007). Additionally Vogel et al. proposed a model where AhR and 
RelB synergistically act in immune responses (Vogel et al. 2007). Therefore we investigate 
the role of AhR and RelB interplay in LCs upon NiSO4 stimulation. 
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3. Aryl hydrocarbon receptor 
 
3.1. AhR signaling and structure: 
The aryl hydrocarbon receptor (AhR) belongs to the basic helix-loop-helix/Per-Arnt-Sim 
(bHLH/PAS) family of transcriptional regulators. AhR is induced by ligand-binding and was 
first identified about 30 years ago in the field of pharmacology as a major mediator of 
chemical toxicity (Burbach et al. 1992). Environmental pollutants such as polyaromatic 
hydrocarbons (PAHs) or dioxins were identified as ligands of this receptor. Their binding to 
the receptor ultimately leads to the activation of the so-called AhR-gene-battery consisting of 
phase I and II detoxifying enzymes such as cytochrome p450 family members Cyp1A1, 
Cyp1A2 and Cyp1B1 (Hankinson 1995; Nebert et al. 1993). These classes of enzymes 
ensure the biotransformation of low molecular weight chemicals and their excretion of the 
cell. Depending on chemical properties such as the receptor binding affinity, metabolizing 
capacity and the length of exposure it is possible that the biotransformation itself is blocked 
or metabolic intermediates accumulate and harm the cell by toxic effects. For example PAHs 
are known to be metabolized quickly after AhR induction by the actions of the detoxifying 
enzymes thereby rendering the chemicals water soluble and enabling excretion. Dioxins on 
the contrary have the highest binding affinities for AhR and are not properly metabolized 
which leads to prolonged AhR activity and accumulation of dioxins inside the cell where they 
trigger toxic effects. Dioxin toxicity in humans has gained great awareness because of 
multiple tragic incidents. While the Vietnam war the US military used the defoliant agent 
orange in a wide geographical scale as a military strategy to weaken guerilla fighters. For 10 
years U.S. military planes atomized huge amounts of Agent Orange over wide landscapes. 
Only later it was discovered that the agent orange had been contaminated with the highly 
toxic AhR ligand 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD). According to estimates about 
half a million of people had been intoxicated or died immediately. Another half million of 
children had birth defects (York and Mick 2008). Another tragic incident happened in Seveso, 
Italy, where a chemical accident led to the release of a TCDD cloud which contaminated a 
wide area. Common symptoms of dioxin intoxication range from hepatocellular damage, 
thymic involution, immune suppression, chloracne, epithelial hyperplasia, teratogenesis to 
tumor promotion and birth defects in newborns (Sweeney and Mocarelli 2000).  
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Structurally the Ah-receptor is comprised of an N-terminal bHLH domain for DNA binding and 
dimerization. This part also harbors the nuclear localization and export sequences (NLS and 
NES) which regulate receptor shuttling. In the center of the receptor is the PAS domain with 
two degenerate repeats (A and B) which not only serve signal sensor purposes by ligand 
binding but also mediate heterodimerization with ARNT, DNA recognition and chaperone 
interactions. The C-terminus has a transactivation domain for receptor transformation and 
potential co-activator recruitment (Stevens et al. 2009).  
The inactive AhR protein is located in the cytoplasm and forms a multi-protein complex with 2 
chaperone molecules heat shock protein 90 (Hsp90) (Heid et al. 2000), one X-associated 
protein 2 (XAP2) (Meyer et al. 1998), one co-chaperone molecule p23 (Kazlauskas et al. 
1999) and the aryl hydrocarbon associated 9 (Ara9) protein (Carver et al. 1998). Exogenous 
AhR-ligands diffuse into the cell and bind to AhR which subsequently undergoes a 
conformational change leading to the exposure of a nuclear localization sequence (NLS) in 
the N-terminal part of the protein (Ikuta et al. 1998). The multiprotein complex is then 
translocated to the nucleus where it dissociates from the chaperone molecules and binds to 
AhR nuclear translocator (ARNT) protein (Reyes et al. 1992). This AhR/ARNT heterodimer 
harbors high DNA binding affinity and targets xenobiotic response elements (XREs) in the 
promoter and enhancer regions of particular genes and turns on their expression (Swanson 
et al. 1995). After transcription induction the receptor is exported to the cytoplasm where it 
gets ubiquitinylated and finally degraded in the proteosome (Davarinos and Pollenz 1999). 
The receptor regulates itself via a negative feedback loop by inducing the expression of the 
aryl hydrocarbon receptor repressor (AHRR) which competes with AhR for ARNT 
dimerization (Mimura et al. 1999; Watanabe et al. 2001).  
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However in the last decade the receptor began to attract interest of immunologists as lots of 
the above mentioned physiologic consequences of dioxin intoxication led to immune 
suppressive disabilities. Apart from this, genomic screening analysis revealed that lots of 
genes involved in innate immune responses harbor a considerable amount of XREs in their 
promoters (Sun et al. 2004). Furthermore it is intriguing that many cell types involved in 
immune responses express AhR receptor protein (also reviewed in (Kerkvliet 2009). 
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Table 2: XREs of genes involved in innate immune responses 
Adapted from Kerkvliet et al. 2009 as summarized from Sun et al. 2004 
Innate 
response 
genes 
XREs 
Receptor 
genes 
DREs 
Associated 
molecules 
DREs 
Tlr1 5     
Tlr 2 2     
Tlr 3 3     
Tlr 4 5     
Tlr 5 9     
Tlr 6 3     
Tlr 7 5     
Tlr 8 2     
Tlr 9 3     
Il1  Il1r1 5 Irak1 5 
  Il1r2 7 Irak1bp 7 
    Irak4 4 
    Il1rap 12 
Il6 3     
Il18 10 Il18r1 3 Il18bp 1 
    Il18rap 1 
      
Tnfα 1     
 
3.2. AhR ligands and their implication in immune responses: 
First of all it has to be said that there are some determining criteria in the ligand 
characteristics which are important for AhR activation and subsequent cellular effects. The 
AhR ligand spectrum is very wide. Ligands are characterized into endogenous and 
exogenous ligands (Denison and Nagy 2003). There are not only environmental pollutants 
binding to AhR and inducing toxic responses but also physiologic ligands play a crucial role 
in normal processes such as immune control and regulation. In the last decades a multitude 
of distinct ligands and alternative signaling pathways contributes to the complexity of the 
signalosome of AhR. Generally it is believed that AhR triggering leads to an overall immune 
suppression as lots of studies with the highly toxic AhR agonist TCDD have revealed. 
However newly discovered endogenous physiologic AhR ligands such as indigorubins, 
bilirubin, lipoxin A4 or oxidized low density lipoprotein (oxLDL) are implicated in modulating 
rather than initiating or suppressing immune responses. Apart from this, dietary compounds 
such as flavonoids, bisphenyls, indigorubins or indols were also identified to bind to AhR and 
induce anti-inflammatory and immune-regulatory effects (Benson and Shepherd 2011). (also 
reviewed in (Kerkvliet 2009; Nguyen and Bradfield 2008) 
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Moreover tryptophan derivates are another important class of endogenous ligands. 
Indoleamine 2,3-dioxygenase (IDO) is an immune-suppressing enzyme of the tryptophan 
metabolism and is present in multiple organs in the organism. Vogel et al. showed that AhR 
activation leads to the induction of IDO (Vogel et al. 2008). It produces kynurenin from 
tryptophan and thereby generates a potent AhR ligand. Kynurenin has been implicated in the 
progression of cancer as a patho-physiological factor that suppresses antitumor immune 
responses and promotes tumor progression (Opitz et al. 2011). In addition to this it has also 
been shown that kynurenin produced in DCs and the subsequent activation of AhR leads to a 
negative regulatory effect on the balance of Treg versus Th17 T-cell differentiation thereby 
significantly influencing the outcome of the immune response (Nguyen et al. 2010). On the 
other hand the tryptophan derivate 6-formylindolo[3,2-b]carbazole (FICZ) is a high affinity 
AhR ligand which is produced in the skin upon UVB irradiation and is quickly metabolized 
after AhR induction (Fritsche et al. 2007). Interestingly, this ligand is reported to rather induce 
than suppress immune reactions by favoring Th17 T-cell differentiation and IL-22 production 
leading to worsened autoimmune disease in an EAE mouse model (Veldhoen et al. 2008). 
Quintana et al. pose a model in which AhR activity controls and regulates differentiation of T-
cells towards a Th17 or Treg phenotype thereby significantly influencing the outcome of an 
immune response (Quintana et al. 2008). In our studies we use FICZ as representative 
endogenous ligand with a concentration of 100nm. VAF347 on the other hand is a 
pharmacological drug designed by Novartis. It has been characterized as tryptophan derivate 
and potent exogenous AhR agonist (Lawrence et al. 2008). Studies revealed anti-
inflammatory and autoimmune-suppressive effects triggered by diminishing the up-regulation 
of maturation markers such as CD86 and HLADR and a decrease in IL6 production 
(Ettmayer et al. 2006). It was further shown that VAF347 administration prolonged graft 
survival in a pancreatic transplantation model. Additionally mice treated with VAF347 yield a 
higher count of regulatory Treg cells (Hauben et al. 2008). For our experiments we use 
VAF347 as representative exogenous AhR ligand with a concentration of 100nm.  
Other exogenous ligands are predominantly environmental pollutants. The most famous 
ligand is TCDD, a tetra-chlorinated dioxin which is not metabolizable and binds AhR with 
very high affinity. It induces immune-suppressive effects in a multitude of models. The 
immune suppressive effects in mice models treated with TCDD range from suppression of 
antibody-producing B-cells and CTL response to prolonging graft-survival and severe 
impairment of virus infection clearance (reviewed in (Kerkvliet 2009). A tremendous amount 
of studies exists for this AhR agonist, although it might not be the right ligand to study the 
physiological role of AhR in the immune system as TCDD leads to a prolonged and 
persistent AhR activation. This mechanism could mask subtle differences in AhR signaling by 
simply inducing toxic-related symptoms. Nonetheless TCDD was the most important AhR 
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ligand for elucidating molecular mechanisms of AhR activation. Another class of exogenous 
ligands are the non-halogenated polycyclic aromatic hydrocarbons (PAHs) which affect the 
cell rather by toxic than by immune-suppressive effects. PAHs such as benzo(a)pyrene 
diffuse into the cell and bind to AhR, thereby activating the transcriptionally active receptor. 
The main difference between dioxins and PAHs is their susceptibility to cellular metabolism. 
Whereas dioxins are not degradable and accumulate in the cell, PAHs are rapidly 
metabolized by AhR-induced detoxifying enzymes such as the Cyp family of enzymes. 
During this process toxic intermediates are generated which harm the cell by multiple ways, 
including diol-epoxide- mediated DNA damage (Davila et al. 1995; Mann et al. 1999; Ward et 
al. 1985).  
Apart from these AhR functions in terminally differentiated cells there have been reports of a 
physiologic role of AhR in the regulation of HSCs and other stem/progenitor cell populations. 
AhR expression is essential for quiescence maintenance in HSCs whereas down regulation 
of AhR enables cells to proliferate pointing towards a negative regulatory function of AhR in 
hematopoiesis (reviewed in (Singh et al. 2009). Additionally Boitano et al. recently published 
a report about an AhR antagonist, StemRegenin 1(SR1), which promotes the expansion of 
human CD34 positive hematopoietic stem cells (Boitano et al. 2010). In our laboratory we 
could show that AhR triggering via VAF347 leads to an inhibition of LC differentiation from 
monocytic precursors which also underlines the negative regulatory function in hematopoietic 
differentiation processes (Platzer et al. 2009). 
 
3.3. AhR signaling cascades and the alternative non-genomic signaling pathway: 
For a long time the dogma in AhR biology was that the receptor can only signal through the 
classical genomic pathway of ligand binding and subsequent ARNT heterodimerization. It 
was believed that only this complex is in turn able to initiate transcription. This basic model of 
AhR action was mostly defined by studies which used TCDD as AhR ligand. Indeed there are 
lots of reports showing inflammatory responses in a TCDD-AhR signaling cascade-
dependent manner. Vogel et al. reported that TCDD treatment of wild-type mice led to an 
induction of keratinocyte chemoattractant (KC) and monocyte chemoattractant protein 1 
(MCP-1) in various organs in an AhR-dependent manner. Furthermore these 
chemoattractant molecules led to an infiltration of macrophages into these organs (Vogel et 
al. 2007). However it has always been a problem to solemnly explain all elicited inflammatory 
effects of TCDD by the oversimplified model of TCDD induced AHR/ARNT mediated gene 
transcription. For instance Sun et al. made a genome wide screening analysis of human, 
mouse and rat DNA for XRE sequences. He identified 2437 genes of which 48 were 
conserved throughout all species. Astonishingly only 19 genes were positionally conserved 
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of which only 7 were responsive to TCDD. In the end only 6 genes induces TCDD dependent 
intracellular changes and all of these genes harbor detoxifying functions (Sun et al. 2004). 
TCDD intoxication also leads to pronounced immune suppression which was so far not 
explainable with regard to the classical genomic pathway and the XRE-mediated TCDD 
responsiveness of genes (reviewed in (Matsumura 2009)). In the last years there has been a 
multitude of reports showing alternative AhR signaling pathways where ARNT is not involved 
as critical factor. The group of Fumio Matsumura was the first to show that kinase activity 
was involved in early TCDD administration to rats. In more detail they implicated the cAMP-
dependent protein kinase (PKA), protein kinase C (PKC), tyrosine kinases and Src kinase 
pp60c-src in the process of TCDD activation and that these signaling pathways lead to the 
activation of EGF receptor which in turn plays a crucial role in the wasting syndrome of dioxin 
intoxication (Bombick et al. 1985; Bombick and Matsumura 1987). Also other groups 
reported of an immediate and rapid increase of free Ca2+-concentration in TCDD treated 
Hepa1 cells (Puga et al. 1992). Nebert et al. even directly connected the TCDD induced Ca2+ 
rise to signal transduction activity of AhR leading to an activation of transcriptionally active 
proteins such as AP-1 (Nebert et al. 1993). The Matsumura group further emphasized that 
TCDD treatment of the MCF10a cell line led to an immediate increase of arachidonic acid 
(AA) in the culture medium. AA is released by the cytosolic phospholipase (cPLA2) which is 
activated by elevated Ca2+ levels. These immediate effects were dependent on AhR but 
independent of ARNT and Src kinase. Therefore they conclude that TCDD activated AhR 
induces an intracellular Ca2+ increase triggering the activity of cPLA2. Next the activated 
cPLA2 activates the Src kinase which then induces the expression of the pro-inflammatory 
gene Cox-2 via AP-1 transcription factor (Dong and Matsumura 2008). Park et al. could 
further show that TCDD administration to the MCF10a cell line led to the suppression of 
growth and differentiation via Src kinase induced ERK MAPK signaling (Park et al. 2004). 
Interestingly Scullio et al. investigated the same TCDD mediated early signaling mechanisms 
but found different results in the U937 cell line differentiated macrophages which more likely 
resemble immunologic cells than the epithelial cell line MCF10a. TCDD activated 
macrophages respond with the production of pro-inflammatory cytokine TNFα thereby clearly 
underlining the immunogenic capacity of the toxic compound TCDD. However the striking 
difference was that the Ca2+ level increase and subsequent cPLA2 activation led to Src 
kinase-independent Cox-2 gene expression (Sciullo et al. 2008). Apart from this nongenomic 
AhR signaling pathway there are other implications of alternative signaling cascades in AhR 
function. In more detail, Ikuta et al. reported that AhR intracellular localization is regulated by 
cell density and cell-cell contact signals. They identified Ser-68 in the nuclear export 
sequence as phosphorylation target upon accumulation of activated AhR in the nucleus. The 
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Ser-68 phosphorylation happened in a p38 MAPK, okadaic acid and Ca2+ concentration 
dependent way (Ikuta et al. 2004).  
 
Nowadays the involvement of MAPK signaling in AhR function is accepted although clear 
mechanisms of action are lacking due to an immense diversity depending on the cell type, 
environmental surrounding and the ligand used for AhR activation. However MAP kinase 
signaling pathways are implicated in receptor shuttling, immune response modulation by 
enhancing, repressing or termination of AhR signaling (reviewed in (Henklova et al. 2008)). 
P38 MAPK was implicated in TCDD-mediated gene transcription in mouse and human 
hepatoma cell lines, as inhibition of p38 signaling by a chemical inhibitor suppressed 
transcription of AhR target genes (Shibazaki et al. 2004). Tan et al on the other hand 
reported the opposite, namely the induction of ERK and JNK signaling but not p38 MAPK 
upon TCDD activation in an AhR-independent way (Tan et al. 2002). Another level of 
complexity was reached when Weiss et al. reported that c-jun transcription factor (JNK 
MAPK), is activated in an AhR-dependent p38 MAPK signaling cascade (Weiss et al. 2005) 
(reviewed in (Puga et al. 2009). In our experiments we focus on the question which MAPK 
signaling cascade triggers the nuclear translocation of AHR in in-vitro PGN-activated LCs. 
With this approach we want to shed light on the situation in activated DCs by other stimuli 
than exogenous AhR ligands with respect to an endogenous physiologic role of AhR in DC 
maturation. For this purpose we make use of special MAPK inhibitors discussed in chapter 
2.7.. 
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3.4. Role of AhR in DCs: 
As it became obvious that AhR plays an important role in immune responses, researches 
started to investigate various cell types of the immune system for potential effects of AhR 
activity. As described above DCs have a pivotal role in linking the innate to the adaptive 
immune response. DCs are therefore the lynchpin in eliciting proper immune responses. In 
addition to this our lab and others showed that DCs express high levels of AhR implicating a 
physiologic cell-specific role for this receptor. Jux et al. reported that LCs of AhR-deficient 
mice show a reduced potential to up-regulate co-stimulatory molecules and down-regulate 
phagocytic capacity upon contact hypersensitivity pointing towards a role of AhR in LC 
maturation (Jux et al. 2009). The results of Bankoti et al. are in agreement with this notion 
because they indicate an increased MHC class II, CD40 and CD86 expression and 
augmented pro-inflammatory cytokine production (IL-6, TNFα) upon TCDD-induced AhR 
signaling. Additionally they saw down-regulated RelA levels but an increase of RelB upon 
TCDD administration to BMDCs from mice. Interestingly these effects were strictly AhR-
dependent but not exclusively XRE-mediated (Bankoti et al. 2010). Dalei Wu et al. were the 
first to pose a model of ligand-independent AhR signaling interaction with classical TLR and 
NFκB mediated transcriptional immune responses. They treated wild-type and AhR knock-
out mice with LPS and found that LPS induced gene transcription was impaired in a tissue 
and time-dependent manner as were the binding affinities of classical transcription factors 
such as NFkB, AP-1 and C/EBP (Wu et al. 2011). Nguyen et al. further reported that BMDCs 
of AhR-deficient mice are unable to up-regulate IDO. This enzyme is in turn needed to 
generate Kynurenin from tryptophan. Kynurenin is a known AhR ligand and influences the T-
cell balance between Th17 and Treg cells. This group implicates a negative immune-
regulatory role for AhR in LPS or CpG induced immune reaction (Nguyen et al. 2010). There 
exists a large body of proof that AhR in DCs is necessary to further regulate AhR-dependent 
immune regulatory functions in other cell types such as T-cells (Quintana et al. 2008; 
Veldhoen et al. 2008). Benson et al. could proof that dietary non-toxic AhR ligands such as 
indole-3-carbinol (I3C) and indirubin-3’-oxime (IO) induce immune-suppressive and anti-
inflammatory effects in BMDCs from mice. Maturation markers such as CD40 and CD54 
were decreased but MHC class II and CD80 were increased. Pro-inflammatory cytokines 
such as TNFα, IL-6, IL-12 and IL-1β were decreased while immune suppressive cytokine IL-
10 was increased. Immune regulatory enzymes such as IDO were up-regulated and T-cell 
stimulatory capacity was altered towards Treg induction. All these effects were partially AhR-
mediated (Benson and Shepherd 2011). VAF347, a tryptophan derivate and anti-
autoimmunity drug mediates its effects in DCs. In an allergic asthma mouse model 
researchers could show that AhR induction with VAF347 ligand decreases HLADR and 
CD86 maturation marker expression in DCs. In addition VAF347 treated DCs display a 
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diminished potential of proliferation and IL-2 production in T-cells (Ettmayer et al. 2006). 
VAG539 (pro-drug of VAF347 which gets converted in vivo) administration to mice and 
subsequent isolation and transfer of DCs to transplanted mice markedly prolongs graft 
survival. The same is true for VAF347 in-vitro differentiated BMDCs (Hauben et al. 2008). 
 
3.5. AhR interplay with candidates other than ARNT and its implication: 
So far we have learnt about the genomic and nongenomic signaling pathway of AhR. Further 
complexity was added by the various MAPK signaling cascades implicated upstream and 
downstream of AhR signaling in immunologic responses. In the last decade the controversial 
discussion about distinct AhR functions in immunologic processes even gained intricacy 
when researchers found that AhR is able to interact with NFκB family members (Tian et al. 
2002). AhR was reported to physically interact with RelA and thereby inhibit typical RelA 
driven transcription (Tian et al. 1999). Ruby et al made an interesting finding when they 
treated a dendritic cell line with TCDD and subsequently activated the cells with TNFα or 
CD40. They observed that the translocation of RelA/p50 heterodimers to the nucleus was 
suppressed. At the same time AhR binding to RelA seemed increased while DNA binding 
was blocked. Interestingly inhibitory p50 homodimers were not affected by TCDD-activated 
AhR and could freely bind to DNA. The authors pose a model in which activated AhR alters 
the balance between RelA/p50 heterodimers and p50 homodimers which leads to the defects 
in DCs resulting in immune suppression (Ruby et al. 2002). Nevertheless there were also 
reports suggesting a positive transcriptional role of AhR/RelA cooperation. Namely Kim et al. 
observed an AhR/RelA heterodimer which binds to NFκB binding sites in the promoter of c-
myc and transactivates its transcription in breast cancer cell lines (Kim et al. 2000). Apart 
from this, AhR also interacts with RelB although this interaction tends to augment 
transcription of immunologic genes such as cytokines and chemokines. Vogel et al. reported 
that TCDD-mediated stimulation of U937 macrophages resulted in the induction of 
chemokines in an ARNT-independent way but RelB was obligatory. They further proposed 
that AhR and RelB physically interact and bind to a novel AhR/NFκB binding site in the 
promoters of these genes (Vogel et al. 2007). Vogel et al. further refined their model and 
proposed that the chemokine induction is AhR and protein kinase A (PKA) dependent. 
Activated AhR and RelB physically interact and bind to novel sites in the DNA thereby linking 
two signaling pathways. Nonetheless the authors claim that classical NFκB sites normally 
targeted by RelB/p52 heterodimers can also serves as target for the novel AhR/RelB 
heterodimer even without stimuli indicating a normal physiological role (Vogel et al. 2007). 
Later the same group reported about the involvement of RelB and AhR in TCDD-stimulated 
breast cancer cell lines by forming an AhR/RelB-heterodimer which ultimately leads to a 
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pronounced IL-8 over-expression (Vogel et al. 2011). To sum up the findings by Vogel et al., 
the group proposes a model in which AhR/RelB heterodimers link the classical AhR/ARNT 
pathway and the alternative NFκB pathway (Vogel and Matsumura 2009).  
 
In our studies we focus on the question whether AhR and RelB interplay in CD34 derived in-
vitro generated LCs upon NiSO4 activation.  
Baglole et al. also reported about an AhR-dependent regulation of RelB in lung fibroblasts. 
AhR-deficient fibroblasts showed a heightened tobacco-smoke induced Cox-2 and 
Prostaglandine production and a loss in RelB expression whereas the symptoms in AhR-
deficient fibroblasts transfected with an AhR expressing plasmid, were attenuated by a 
mechanism that maintained RelB expression (Baglole et al. 2008). Another group 
investigated the mechanism of the synergistic induction of IL-6 by AhR and inflammatory 
signaling. They came to the conclusion that TCDD-activated AhR primes the IL-6 promoter 
by binding to upstream non-consensus XREs thereby facilitating IL1β-induced RelA/p50 or c-
REL/p50 binding. Furthermore they could pose a mechanism because they subsequently 
observed the recruitment of histone deacetylase (HDAC) 1 and 3 to AhR primed promoter, 
reorganizing repressive complexes on DNA and priming the locus for transcription (DiNatale 
et al. 2010). Jensen et al. reported the opposite phenomenon in a bone-marrow derived cell 
line. They saw a TCDD-activated AhR-dependent inhibition of IL-6 transcription upon LPS 
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activation. At least for AhR agonist 7,12-Dimethylbenz[a]anthracen (DMBA) they report a 
decrease in RelA/p50 and c-Rel/p50 heterodimer binding at the IL-6 promoter (Jensen et al. 
2003). Again it becomes obvious that there is no common signaling mechanism for AhR-
mediated effects in the immune system. Every cell type investigated shows a distinct pattern. 
This further underlines the concept that AhR signaling receives multiple crosstalk from other 
signal transduction pathways and that this process is cell-type, micro-environment and cell-
state specific. 
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Material and Methods 
4. Cell culture: 
4.1. Media, buffers and solutions: 
Table 3: Media   
Media Supplementations  Company 
X-Vivo Serum-free hematopoietic cell 
medium  
125U/ml penicillin 
125U/ml streptomycin 
2,5mM GlutaMAX 
Lonza 
Cell-Gro DC Serum-free dendritic cell medium 125U/ml penicillin 
125U/ml streptomycin 
2,5mM GlutaMAX 
CellGenix 
RPMI-1640 (Roswell Park Memorial Institute) 
Cell line medium for suspension 
culture 
10% FCS 
125U/ml penicillin 
125U/ml streptomycin 
2mM L-gluatmine 
Sigma 
Aldrich 
DMEM (Dulbecco´s modified eagle´s 
medium) 
Cell line medium for adherent culture 
10% FCS 
125U/ml penicillin 
125U/ml streptomycin 
2mM L-gluatmine 
Sigma 
Aldrich 
PBS Phosphate-buffered saline - Sigma 
Aldrich 
 
Table 4: Buffers and solutions  
Buffers/solutions Ingredients 
10xPBS 400g NaCl (Roth) 
10g KCl (Roth) 
72g Na2HPO4 (Roth) 
10g KH2PO4 (Roth) 
adjust to pH 7,4 
in 5l dH2O 
PBST 1x PBS 
0,05% Tween20 (Roth) 
PBSTT 1xPBS 
0,1% Tween20 (Roth) 
0,05% TritonX-100 (Polysciences, Inc.) 
1x PBS/BSA/Azide 1xPBS 
20% BSA (Roth) 
0,4% Na3N (Roth) 
Beriglobin Beriglobin (CSL Behring) diluted 1/8 in 1xPBS 
MACS buffer 250ml 10xPBS 
20mM EDTA 
5% BSA 
Dilute 1/10 with H2O dest. 
10x blotting buffer 30,3g Tris (Roth) 
144g Glycin (Roth) 
in 1L dH2O 
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10x SDS-PAGE buffer 30,2g Tris (Roth) 
144g Glycin (Roth) 
10g SDS (Roth) 
in 1L dH2O 
Stripping buffer 100ml 20%SDS (Roth) 
2,5ml 1M Tris/ HCl pH 7,5 
7,3ml β-mercaptoethanol (Sigma) 
830,2ml dH2O 
8% separating gel 2134μl 30% Acrylamid/Bis (Biorad) 
2000μl Tris/HCl pH 8,8 
3736μl dH2O (Fresenius) 
40μl 20% SDS (Roth) 
10μl TEMED (Biorad) 
80μl 10% APS (Biorad) 
4% stacking gel  396μl 30% Acrylamid/Bis (Biorad) 
378μl Tris/HCl pH 6,8 
2196μl dH2O (Fresenius) 
15μl 20% SDS (Roth) 
5μl TEMED (Biorad) 
20μl 10% APS (Biorad) 
4x sample buffer 0,5M Tris/HCl pH 6,8 
40% Glycerol (Roth) 
4% SDS (Roth) 
5μl/ml Bromphenolblue (Roth) 
5% β-mercaptoethanol (Sigma) 
2xHBS 8g NaCl (Roth) 
6,5g HEPES (Sigma) 
105mg NaH2PO4 (Roth) 
in 500ml dH2O (Fresenius) 
adjust to pH 7,00 
2M CaCl2 14,70g CaCl2 (Roth) in 50ml H2O 
dH2O Aqua bidest. “Fresenius” (Fresenius Kabi) 
ACK lysis buffer 8,3g NH4Cl (Roth) 
1g KHCO3 (Roth) 
37,2mg Na2-EDTA (Roth) 
in 1L dH2O 
adjust to pH 7,2-7,4 
sterilize with 0,2μm filter 
Blocking solution 0,2g BSA (Roth) 
100µl of a 10% Tween20 stock solution 
5µl of a 20% Sodium azide stock solution 
Fill up with 1xPBS to 10ml 
 
4.2. Reagents and cytokines: 
Table 5: Reagents   
Reagents Company Working concentration 
FCS  
(fetal calf serum) 
Gibco/Invitrogen Heat inactivated at 65°C water 
bath for 30 min prior to use 
L-glutamine Sigma Aldrich 2mM 
GlutaMAX Gibco/Invitrogen 2,5mM 
Trypsin-EDTA Sigma Aldrich 3ml/10cm dish 
Penicillin Sigma Aldrich 125U/ml 
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Streptomycin Sigma Aldrich 125U/ml 
Donkey-anti-human 
IgG 
Jackson ImmunoResearch 10µg/ml 
Delta-1 IgG Kindly provided by Bernstein ID 1µg/ml 
Chloroquin Sigma Alrich 50mM  
Retronectin Takara Bio 30µg/ml 
 
Table 6: Cytokines    
Cytokines  Company Working 
concentration 
GM-CSF Granulocyte-
macrophage 
colony stimulating 
factor 
Kindly provided by 
Novartis Institutes of 
Biomedical Research 
and PeproTech 
100ng/ml 
TPO Thrombopoietin PeproTech 50ng/ml 
Flt3Ligand Fms-related 
tyrosine kinase 3 
ligand 
PeproTech 50ng/ml 
SCF Human stem cell 
factor 
PeproTech 20ng/ml 
TNF-α Tumor necrosis 
factor alpha 
PeproTech 2,5ng/ml 
TGF-β1 Transforming 
growth factor 
beta1 
R&D Systems GmbH 0,5ng/ml for LC 
10ng/ml for moLC 
IL4 Interleukin 4 PeproTech 2,5ng/ml 
 
4.3. AhR ligands and activation stimuli: 
Table 7: AhR ligands   
AhR ligands Company Working 
concentration 
VAF347 4-(3-chlorophenyl)-N-[4-
(trifluoromethyl)phenyl]pyrimidin-2-
amine, 4-(3-Chlorophenyl)-N-(4-
(trifluoromethyl)phenyl)pyrimidin-2-
amine 
Kindly provided 
by Novartis 
100nm 
FICZ 6-formylindolo[3,2-b]carbazole Biomol 
International, Inc. 
100nm 
 
Table 8: Activation stimuli   
Activation stimuli Company Working 
concentration 
PGN Peptidoglycan Sigma Aldrich 10µg/ml 
LPS Lipopolysaccharide Sigma Aldrich 2µg/ml 
SDS Sodium dodecyl sulfate Roth 20µg/ml 
NiSO4 Nickel sulfate Roth 500µM 
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4.4. Isolation of cord blood CD34 and peripheral blood CD14 positive cells: 
Cord blood is obtained from full-term deliveries of healthy donors. The Medical University of 
Vienna review board approved these studies and informed consent is provided according to 
the Declaration of Helsinki. Human peripheral blood samples from healthy donors and cord 
blood samples are diluted 1:1 with 1xphosphate buffered saline (1xPBS). To separate the 
mononuclear cell fraction from serum, erythrocytes and granulocytes the diluted blood is 
covered over a density gradient of lymphoprep (Axis Shield PoC AS) and centrifuged without 
deceleration for 25 minutes with 1500 rpm. The mononuclear cell ring is carefully harvested 
and washed with 1xPBS. To get rid of contaminating erythrocytes the cells are incubated in 
4°C cold ACK lysis buffer for 10 minutes on ice. After washing the cells for 10 minutes in 
PBS with 1200 rpm the isolation is carried out according to the manufacture’s protocol. For 
CD34 positive hematopoietic stem cell isolation from cord blood we use the EasySep human 
CD34+ selection kit (StemCell Technologies Inc.). CD14 positive monocyte isolation from 
peripheral blood is achieved by labeling the mononuclear cell fraction with 20µl of CD14-PE 
labeled antibody (BioLegend Inc) for 15 minutes on ice. After washing with 1xPBS for 10 
minutes with 1200rpm the cells are coupled to MACS-anti-PE magnetic beads (Miltenyi 
Biotech) for 15 minutes on ice. After another washing step with 1xPBS for 10 minutes with 
1200rpm cells are dissolved in MACS buffer and isolated over LS MACS columns (Miltenyi 
Biotech) according to manufacturer´s protocol. Isolated cell purity is analyzed by FACS 
(~90%). 
 
4.5. Cell lines: 
The Phoenix-GalV packing cell line (PhGP) is cultured in DMEM complete medium 
(supplemented with 10%FCS, 2mM L-glutamine, 125U/ml of both Penicillin and 
Streptomycin) in NunclonTMΔSurface 10cm culture dishes (Nunc) and split every 2nd day 1/7-
1/9. For splitting adherent cells we first aspirate the culture supernatant and add 3 ml of 
Trypsin-EDTA (Sigma Aldrich). When cells start to detach, the reaction is stopped by adding 
8ml of DMEM medium. After a washing step cells are split 1/7 and seeded in a new dish. 
This cell line is maintained at 37°C with 5% CO2. 
 
4.6. Freezing and thawing of cells:  
~1*10^6 cells are pelleted by a 5 minute centrifugation step with 1200rpm. The pellet is 
dissolved in FCS + 10%Dimethyl Sulfoxide (DMSO; Sigma Aldrich) and placed in a Mr. 
Frosty freezing container (Sigma Aldrich) and stored at -80°C. For thawing the cells, we used 
10ml of pre-warmed medium to dissolve the cells and wash them in a 5 minute centrifugation 
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step at 1200rpm. The cells were then plated in the according medium and maintained at 
37°C and 5% CO2. 
 
4.7. Cell culture and differentiation of primary cells: 
CD34+ hematopoietic stem cells isolated from cord blood are expanded for 3-7 days in 
serum-free X-vivo complete medium in the presence of 50ng/ml of each Flt3L, TPO and 
SCF. The expanded CD34+ cells are then used to in-vitro differentiate interstitial dendritic 
cells (IntDCs) or langerhans cells (LCs). The latter cell type is generated in serum-free Cell 
Gro DC complete medium in the presence of 100ng/ml GM-CSF, 20ng/ml SCF, 50ng/ml 
Flt3L, 2,5ng/ml TNFα and 2ng/ml TGF-β1. After 7 days of differentiation LCs form typical cell 
clusters which can be purified over PBS. The pipette tip is cut off to carefully resuspend the 
cells and transfer them on 8ml 1xPBS in a 15ml falcon tube. The clusters settle on the 
bottom of the tube after 2-5 minutes and the supernatant is discarded. IntDCs are generated 
with a 2-step protocol. First the expanded CD34+ cells are cultured in Cell Gro DC complete 
medium in the presence of 100ng/ml GM-CSF, 20ng/ml SCF, 50ng/ml Flt3L and 2,5ng/ml 
TNFα for 5 days. Afterwards the cells are harvested and centrifuged for 5 minutes with 
1200rpm and seeded 1:2 in RPMI-1640 complete medium in the presence of 100ng/ml GM-
CSF and 2,5ng/ml IL-4 for another 5 day differentiation period.  
CD14 positive monocytes isolated from peripheral blood can either be differentiated into 
monocyte-derived DCs (moDCs) or monocyte-derived LCs (moLCs). To generate moDCs the 
CD14+ monocytes need to be cultured in RPMI-1640 complete in the presence of 100ng/ml 
GM-CSF and 2,5ng/ml IL-4 for 4 days. MoLC generation requires a special coating of the 
culture plates with Notch ligand Delta-1. 24-well non-tissue suspension culture dishes 
(Greiner) are incubated with 10µg/ml donkey-anti-human IgG in PBS for 1 hour at 37°C 
5%CO2. After 1 hour of RPMI complete blocking at 37°C supernatant is discarded and 
1µg/ml Delta-1 in PBS is transferred onto the blocked wells for 3-4 hours at 37°C or overnight 
at 4°C. The CD14+ monocytes are then seeded onto the Delta-1 coated wells in RPMI 
complete medium in the presence of 100ng/ml GM-CSF and 10ng/ml TGF-β1 and incubated 
for 4 days. 
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All primary cells are maintained in an incubator with 37°C and 5% CO2 saturation. 
Table 9: Differentiation models of primary cells 
Adapted from (Haslwanter 2012) 
Precursor Cell type Medium Cytokines Time [d] Reference 
CD34 LC Cell Gro DC  
complete 
GM-CSF, SCF, Flt3L,  
TNFα, TGF-β1 
7 (Strobl et al. 
1996) 
CD34 IntDC Cell Gro DC  
complete   &  
RPMI  
complete 
1st: GM-CSF, SCF,  
Flt3L and TNFα  
 
2nd: GM-CSF, IL-4 
10 (Caux et al. 
1996) 
CD14 moDC RPMI  
complete 
GM-CSF, IL-4 5 (Sallusto and 
Lanzavecchia 
1994) 
CD14 moLC RPMI  
complete 
GM-CSF, TGF-β1  
Delta-1 coated wells 
4 (Hoshino et al. 
2005) 
 
Maturation studies were done after the initial differentiation period. LCs are cluster purified 
whereas the other cell subsets are not purified. The cells are cultured in Cell Gro DC 
complete medium in the presence of 100ng/ml GM-CSF. 2µg/ml SDS, 500µM NiSO4, 2µg/ml 
LPS or 10µg/ml PGN are incubated for 24 hours at 37°C with 5% CO2 saturation. 
 
4.8. Retroviral infection and transfection: 
For the study of a potential RelB/AhR interplay in LC maturation upon NiSO4 treatment, we 
infect CD34+ hematopoietic stem cells with the constitutively active retroviral vector 
pBMNp100ΔN-IRES-GFP (Solan et al. 2002). The amphotropic virus is generated in the 
293T derived packaging cell line Phoenix-GP which is transformed with an E1a adenovirus 
and carries a temperature sensitive T antigen co-selected with neomycin. These cells 
encode two retroviral genes Gag and Pol which enable virus packaging and viral replication 
(Nolan). Phoenix-GP cells are split one day before transfection in the normal 1/7-1/9 ratio 
and seeded onto NunclonTMΔSurface 6cm culture dishes (Nunc) in DMEM complete medium. 
On the next day the vector plasmid is transfected into the packing cell line by calcium-
phosphate precipitation. The DNA precipitate is formed by pipetting together 12µg vector 
DNA, 8µg GalV plasmid DNA, 3µg gagpol plasmid DNA and 63µl 2M CaCl2. After adding 
430µl dH2O and 500µl 2xHBS buffer pH 7.1, the mixture is immediately vortexed for 45 
seconds and incubated at room temperature for 15 minutes. In the meantime 3µl of 50mM 
chloroquin (Sigma Aldrich) are applied drop wise to the Phoenix-GP culture. After 5 minutes 
of incubation the DNA precipitates are carefully pipetted drop wise onto the Phoenix-GP cells 
which are then incubated at 37°C 5% CO2 for 6 hours. Transfection rates is checked by 
FACS, 90-100% transfection efficiency must be achieved for further infection. Then the 
medium is carefully aspirated and 2ml of DMEM complete are carefully added to the cells. 
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2days later the culture supernatant containing the virus particles is filtered through a 0,45µm 
syringe filter (Iwaki) and the cells itself were analyzed for transfection efficiency by FACS. 
The virus producing Phoenix-GP cells are again incubated with 2ml of DMEM complete over 
night. On the next day CD34+ cells are further infected with the viral supernatant. For this we 
coat 24-well non-tissue suspension culture dishes (Greiner bio-one GmbH) with 1mg/ml 
Retronectin (Takara Bio) in 1xPBS over night at 4°C. 700µl of filtered viral supernatant is 
transferred onto the Retronectin-coated wells and incubated for 4 hours at 37°C. 1 day 
expanded CD34+ hematopoietic stem cells isolated from cord blood are dissolved in X-vivo 
medium complete with a cell density of 2*10^4/700µl. 400µl of viral supernatant are carefully 
taken off and 700µl of cells are added onto the wells. CD34 expansion mix is prepared (100µl 
X-vivo complete medium with 50ng/ml of TPO, SCF and Flt3L) and 10µl are added per well. 
On the next day the second infection round is done by carefully exchanging 400µl culture 
supernatant with filtered viral supernatant. The CD34 cells are then again expanded in the 
presence of new expansion mix until the next day. After the infection procedure the infection 
rate is analyzed by FACS. When an infection rate of 60-90% is achieved cells are further 
differentiated into LCs (see differentiation of primary cells chapter 4.7).  
 
5. Immunfluorescence stainings: 
5.1. Fluorescent activated cell sorting (FACS analysis): 
Surface marker expression is analyzed by FACS. Up to 5*10^5 cells are stained per micronic 
tube (Thermo Scientific). First the cells are washed with 1xPBS/BSA/Azide for 5 min at 300g 
centrifugation at 4°C. All further steps are carried out on ice and incubation times at 4°C in 
the fridge. The supernatant is discarded and the remaining 50µl of cell suspension is 
vortexted and incubated with 10µl beriglobin for 10 minutes at 4°C to block unspecific Fc-
binding of the antibodies. Afterwards 10µl of each antibody dilution are added to the 
beriglobin blocked cell suspension and incubated for 20-30 minutes at 4°C. In case the 
primary antibody is biotinylated instead of directly fluorophore-coupled, cells are washed 
once with 1xPBS/BSA/Azide for 5 minutes at 300g. The secondary antibody (SA-PerCP) is 
incubated for 30 minutes at 4°C. Afterwards cells are washed twice with 1xPBS/BSA/Azide 
and either analyzed right away or fixed with 100µl of FIX medium (An der Grub) for 7 minutes 
in the dark and washed once with PBS/BSA/Azide for 5 minutes with 300g. The micronitc 
tube is filled up with PBS/BSA/Azide and stored in the fridge. Thereafter cells can be 
analyzed for up to one week. Prior to analysis cells need to be washed once in 1xPBS to get 
rid of the Azide and supernatant was aspirated. Cells are then vortexted in the remaining 
50µl 1xPBS. All antibody dilutions are made with 1xPBS/BSA/Azide and prepared as 
mastermix before addition to the cells. For flow cytometric analysis of the cells we use the 
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BD LSRII cytometer and data analysis is done with the FlowJo software (BD Biosciences). 
For the list of antibodies used and the corresponding dilution see table 10. 
Table 10: Antibodies for FACS analysis 
Antibody Company Stock concentration 
CD1a-Pacific Blue BioLegends 1/10 
Langerin-PE (CD207) Immunotech 1/10 
E-cadherin-APC BioLegends 1/20 
CD14-APC-Cy7 BD Bioscience 1/30 
CD14-FITC BD Bioscience 1/5 
CD11b-PE-Cy7 BD Bioscience 1/50 
CD40-PE BD Bioscience 1/20 
HLADR-biot BD Bioscience 1/10 
CD80- biotylated BD Bioscience 1/5 
CD83-APC BD Bioscience 1/5 
CD86-FITC BD Bioscience 1/10 
CD86-biotylated BD Bioscience 1/5 
Streptavidin(SA)-PerCP BD Bioscience 1/100 
 
5.2. AhR and RelB staining of moLCs and LCs:  
Cells are harvested and washed once with 1xPBS for 5 minutes at 1200rpm.  
AhR staining: 
Then cells are resuspended in 1xPBS at a concentration of 2-8*10^4cells/50µl. 12-spot 
adhesion slides (Marienfeld) are then prepared by rinsing off the green protection film with 
water and 1xPBS. Afterwards 50µl of the cell suspension are pipetted onto each spot and 
incubated in a liquid chamber for 10-15 minutes at RT. For fixation of the cells the slides are 
incubated in -20°C methanol for 10 minutes and shortly washed in 1xPBS. Next, the cells are 
blocked for 10 minutes with 30µl beriglobin per spot. Primary antibody incubation is done 
over night at 4°C with 1/100 anti-AhR antibody or 1/100 goat IgG antibody in 2%BSA/PBS. 
On the next day slides are washed three times with 1xPBS for 3 minutes before blocking with 
5% donkey serum in 1xPBS for 30 minutes. Secondary antibody donkey-anti-goat-AF488 
coupled (or –AF546 coupled) is diluted 1/500 in 2%BSA/PBS and incubated for 1 1/2hours at 
RT in the dark. After three washing steps of 3 minutes in 1xPBS we do a specificity blocking 
step with 5% mouse serum in 1xPBS for 30 minutes before we counter-stained with CD1a-
AF546 1/750(or –APC coupled 1/50) diluted in 2%BSA/PBS for 4 hours at RT in the dark. 
After another three 3 minute washes in 1xPBS the nuclei are stained with 1/100 dapi dilution 
in 1xPBS for 10 minutes in the dark. Then slides are washed two times 5 minutes in 1xPBS 
and mounted in fluoroshield (Sigma Aldrich) with a cover slip and the edges are sealed with 
nail polish. Microscopic pictures are made with 20x or 40x objectives with a Zeiss LSM700 
confocal microscope at the imaging facility of the medical university of Vienna. 
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RelB staining:  
Cells are resuspended in 50µl 1xPBS and 50µl FIX and PERM solution (ADG Bio Research 
GmbH) is incubated for 15 minutes at RT. After a washing step with 500µl PBS for 5 minutes 
at 1200rpm the cells are resuspended in 1xPBS at a concentration of 2-8*10^4. 12-spot 
adhesion slides (Marienfeld) are then prepared by rinsing off the green protection film with 
water and 1xPBS. Afterwards 50µl of the cell suspension are pipetted onto each spot and 
incubated in a liquid chamber for 20 minutes at RT. For fixation of the cells the slides were 
incubated in -20°C methanol for 3 minutes and 30 seconds in -20°C aceton. Permeabilization 
of the cells is achieved by incubation of the slides in 0,1%TritonX-100 in 1xPBS for 3 minutes 
at RT. Cells are then blocked for 30 minutes in a blocking solution (0,2gBSA, 100µl Tween20 
(of a 10% stock solution) and 5µl sodium azide (of a 20% stock solution) dissolved in a total 
volume of 10ml 1xPBS). The primary antibody incubation is done over night at 4°C in a liquid 
chamber with 1/250 anti-RelB antibody or rabbit IgG antibody dilution in blocking solution. On 
the next day the slides are first washed for 7 minutes in blocking solution and then for 5 
minutes in 1xPBS. Specificity blocking is done with a 5% goat serum in 1xPBS dilution for 30 
minutes before the secondary antibody goat-anti-rabbit-AF488(or –AF546 coupled) 1/500 
dilution in blocking solution is applied for 1 1/2hours in the dark. Thereafter slides are 
washed two times for 5 minutes in 1xPBS before we apply a 5% mouse serum in 1xPBS 
solution for specificity blocking for another 30 minutes. Afterwards we counter-stain with 
1/750 anti-CD1a-AF546 (or –APC coupled 1/50) antibody dilution in blocking solution for 2 
hours at RT in the dark. Then we wash the slides two times 5 minutes with 1xPBS and 
incubate the cells with a 1/100 dapi dilution in 1xPBS for 15 minutes before we wash another 
two times 5 minutes with 1xPBS. Finally, the slides are mounted in fluoroshield medium 
(Sigma Aldrich) with a cover slip and the borders were sealed with nail polish. Microscopic 
pictures were made with 20x or 40x objectives with a Zeiss LSM700 confocal microscope at 
the imaging facility of the medical university of Vienna. 
Table 11: Antibodies for Immunfluoresence stainings on single cells 
Antibody Dilution company 
Ah Receptor (N-19): sc-8088 1/100 Santa Cruz Biotechnology, Inc 
NFκB p50 (C-19): sc-226 1/250 Santa Cruz Biotechnology, Inc 
Goat IgG 1/100 Santa Cruz Biotechnology, Inc 
Rabbit IgG 1/250 Santa Cruz Biotechnology, Inc 
Dapi 1/100 Sigma Aldrich 
Langerin-PE 1/50 Immunotech 
CD1a-APC (HI146) 1/50 BD Biosciences 
CD1a-AF546 1/750 Kindly provided by Elbe-Bürger 
Lab. 
Donkey-anti-goat-AF488 /–AF546 
coupled 
1/500 Invitrogen 
Goat-anti-rabbit-AF488 /–AF546 coupled 1/500 Invitrogen 
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5.3. AhR staining of human skin sections: 
Human skin samples from plastic surgery (abdominoplasty or mammoplasty) are first 
fumigated with Betaisodona (Multipharma Ges.m.b.H.) and subsequently freed from cloth 
and adipose tissue with a scalpel. The dermis and epidermis are then cut in small squares 
and incubated in 24-well plates in 1ml RPMI complete medium with 100ng/ml GM-CSF 
without stimulation and 1µl SDS or NiSO4 stimulation overnight. On the next day the skin 
parts are cryo-frozen in Tissue-Tek O.C.T. compound embedding medium (Sakura) in liquid 
nitrogen and stored at -80°C. Skin sections are then cut with a cryostat and placed on 
microscopic glass slides. After fixing the skin sections with -20°C cold aceton for 10 minutes 
the O.C.T. compound rests are removed and the sections are encircled with a hydrophobic 
pen. Now the samples are blocked for 30 minutes with 2%BSA/PBS at room temperature 
(RT). Primary antibody anti-AhR and the goat-IgG isotype control antibody are dissolved 
1/100 in 2%BSA/PBS and incubated over night at 4°C in a humid chamber. After three 
washing steps with 1xPBS for 5 minutes we block with 10% donkey serum in 1xPBS for 30 
minutes at RT. Secondary antibody donkey-anti-goat-AF488 is dissolved 1/500 in 
2%BSA/PBS and incubated 1 ½ hours at RT in the dark. Thereafter slides are again washed 
three times 5 minutes with 1xPBS and blocked with 10%mouse serum in 1xPBS for 30 
minutes. We counter-stain with 1/50 Langerin-PE antibody dissolved in 2%BSA/PBS for 4 
hours at RT. Slides are again washed three times 5 minutes in 1xPBS. In the end we 
incubate the slides with 1/100 Dapi dye in 1xPBS for 10 minutes. After another threes 
washing steps in 1xPBS for 5 minute the slides are mounted in fluoroshield (Sigma Aldrich) 
with a cover slip. Microscope pictures are taken with a Zeiss LSM700 confocal microscope 
with 20x or 40x objectives at the imaging core facility of the medical university of vienna.  
Table 12: Antibodies for Immunfluoresence staining on skin cryosections 
Antibody Dilution company 
Ah Receptor (N-19): sc-
8088 
1/100 Santa Cruz Biotechnology, Inc 
Donkey-anti-goat-AF488  1/500 Santa Cruz Biotechnology, Inc 
Dapi 1/100 Sigma Aldrich 
Langerin-PE 1/50 Immunotech 
 
6. DNA and protein analysis: 
6.1. qPCR 
For mRNA level determination we use quantitative real-time PCR. We harvest cells, wash 
them once in 1xPBS and count them with the CasyCounter (Schärfe System GmbH). Cells 
are again washed in 1xPBS and the supernatant is discarded. For total RNA isolation we use 
the RNeasy® Mini Kit (Quiagen). All working steps are carried out on an RNAZip treated 
work bench and the pipette tips are filtered. Cells are disrupted by re-suspension in 150µl 
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RLT buffer with 1/100 β-mercaptoethanol by vortexing for 1 minute. At this step samples are 
stored at -20°C and RNA isolation is done later according to the manufacturers´ protocol. 
The thawed samples are mixed with 150µl 70% ethanol and immediately transferred to the 
RNeasy columns and centrifuged for 15 seconds with 8000g. The column is washed with 
350µl RW1 buffer for 15 seconds at 8000g. DNA eradication is done by a 15 minute 
incubation at RT with 80µl of a DNase solution (10µl DNase I stock solution plus 70µl RDD 
buffer (Quiagen)). Finally the column is washed with 350µl RW1 buffer and 500µl RPE buffer 
for 15 seconds at 8000g each and with 500µl of RPE buffer for 2 minutes at 8000g. Before 
RNA elution from the column with RNase-free water (10µl) for 1 minute at 8000g we perform 
an additional centrifugation step for 1 minute at full-speed to get rid of excess liquid. For an 
increased RNA recovery from the column the elution step is repeated with another 10µl of 
RNase-free water. As a next step cDNA is produced from the isolated RNA. For this we use 
16,25µl RNA and mix it with 1µl oligodT primers (25mM) in an eppendorf PCR tube. Primer 
annealing is achieved after 5 minutes of 70°C followed by 5 minute 4°C incubation. 
Afterwards we add 5µl 5x RevertAid [TM] H Minus M-MuLV RT buffer, 1.25µl dNTP mix 
(10mM) , 0,5µl RiboLock RNase Inhibitor (40u/µl) and 1µl of RevertAid [TM] H Minus M-
MuLV RT (200u/µl) (all reagents were obtained from Fermentas). cDNA generation is 
accomplished by a 2-step cycle PCR program starting with 42°C for 1 hour followed by 70°C 
for 15 minutes and cooling down to 4°C. cDNA is stored at -20°C and has to be diluted 1/3 
with RNase-free water before usage for quantitative real-time PCR. However, samples for 
real-time qPCR are pipetted in a 96-well 20µl capillary plate (BioRad). Detection is done with 
the CFX96 Real Time Detection System (BioRad). qPCR mix includes: 5µl Sybr Green mix 
(Life Technologies, Applied Biosystems®), 0,5µl of each forward and reverse primers (10µM; 
MWG Eurofins Operon), 3µl RNase-free water (Quiagen) and 1µl cDNA (1:3 diluted). For 
standard curve cDNA is used 1/3, 1/8, 1/16 and 1/32 diluted. Every condition is pipetted as 
duplets to get an average value. Amplification program is 95°C for 5 minutes followed by 40 
cycles of 95°C (15 seconds) and 60°C (60 seconds) and ends with 4°C cooling. All primers 
are designed with the Primer3 software and ordered from MWG Eurofins Operon. Data 
analysis is done with the BioRad CFX Manager software. Gene of interest mRNA levels are 
normalized to GAPDH mRNA levels. Values represent the fold-change to un-stimulated cells. 
Following primer sequences are used: 
GAPDH primers: 
Forward: 5´-GAAATCCCATCACCATCTTCCAGG-3´ 
Reverse: 5´-CGCGGCCATCACGCCACAGTTTCC-3´ 
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Cyp1a1 primers: 
Forward: 5´-CAGCTGACTTCATCCCTATTC-3´ 
Reverse: 5´-AGCTGGACATTGGCGTTCTCA-3´ 
 
IL8 primers: 
Forward: 5´-GTGTGAAGGTGCAGTTTTGC-3´ 
Reverse: 5´-AATTTCTGTGTTGGCGCAGT-3´ 
 
6.2. Western Blot 
To determine protein levels in cells the method of choice is western blot analysis. Cells are 
harvested, washed once in 1xPBS for 5 minutes at 1200rpm and counted with the 
CasyCounter (Schärfe System GmbH). Then cells are transferred to an 1,5ml eppendorf tube 
and washed again in 1xPBS for 5 minutes at 1200rpm. The cell pellet is vortexed and 
resuspended in an appropriate amount of 4x SDS sample buffer to reach a concentration of 
1*10^5 cells per 10µl 1xSDS sample buffer. To lyse the cells the samples are heated for 15 
minutes at 95°C on a shaking heating block. Finally the western blot samples are stored at -
20°C. Before loading the protein extract (~1/10^5 cells) onto the gel, samples are again 
heated up for 10 minutes at 95°C. We used 8% separating with 4% stacking denaturating 
sodium dodecylsulfate-polyacrylamide gels (SDS-PAGE) for protein separation. 
Electrophoretic protein separation on the gel is done in 1x SDS-PAGE buffer with 80V (start 
with 40V). When the running front of the protein extracts is running out of the gel the gel run 
is stopped and the proteins are transferred onto a polyvinylidenfluorid (PVDF) membrane 
(Immobilon-P, Millipore) with 250mA for 1 ½ hours inside a Biorad Criterion Blotter aperture 
(BioRad) with ice cold 1xblotting buffer with an ice cube to cool the system and an magnetic 
stirring ball to mix the liquid conduction buffer. After this step we make a Ponceau red 
staining (Sigma Aldrich) for 1 second to check proper protein transfer. The red staining is 
washed out with distilled H2O and 1xPBS. Afterwards the membrane is blocked for 45 
minutes in 5% low-fat milk powder in 1x/PBS-T at RT. Primary antibody dilutions are 
incubated over night at 4°C shaking. For the list of antibodies see table 13. On the next day 
the antibody dilution is recovered and the membrane washed in 1xPBS-T three times 10 
minutes shaking. Next the secondary antibody is diluted in 3% low-fat milk/PBS-T and 
incubated for 1 ½ hours at RT shaking. After another three washing steps in PBS-T for 10 
minutes and a last washing step in 1xPBS the membrane is analyzed. Chemiluminescent 
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substrate SuperSignal WestPico and WestDura Kit (Pierce Biotechnology) are mixed 
according to the manufacturers’ protocol and applied onto the membrane. Pictures are taken 
with a Fujifilm Las-4000 developer machine. Actin is used as normalization. Repeated 
incubation with antibodies requires an antibody stripping step in between. Membranes are 
incubated with stripping buffer for 10 minutes at 57°C in a shaking water bath. After two 
times 10 minutes PBS-T washing at RT on a shaker the incubation starts again with 5% low-
fat milk/PBS-T incubation for 45 minutes at RT and subsequent antibody incubations (see 
steps above). Western Blot quantifications are done with the ImageJ program, calculations 
are done in Microsoft Excel and statistical analysis is carried out with the Graphpad Prism4 
software. Protein levels are normalized to the Actin levels. 
Table 13: Antibodies for Western Blot analysis 
Antibody company Working concentration 
AhR Santa Cruz Biotechnology, Inc. 1/500 (in 3% milk/PBS-T) 
RelB Santa Cruz Biotechnology, Inc. 1/500 (in 3% milk/PBS-T) 
Actin Sigma Aldrich 1/1000 (in 3% milk/PBS-T) 
phospho-p38 Cell Signaling Technology, Inc. 1/500 (in 5%BSA/TBST) 
VDR Santa Cruz Biotechnology, Inc. 1/500 (in 3% milk/PBS-T) 
p65 Santa Cruz Biotechnology, Inc. 1/500 (in 3% milk/PBS-T) 
PU.1 Santa Cruz Biotechnology, Inc. 1/500 (in 3% milk/PBS-T) 
Goat-anti-rabbit-HRP Thermo Scientific (Pierce) 1/5000 (in 3% milk/PBS-T) 
Donkey-anti-goat-HRP R&D Systems GmbH 1/2500 (in 3% milk/PBS-T) 
 
6.3. ELISA measurement of cytokines in the culture supernatant: 
About 1*10^6 (moLCs) to 1*10^5 (LCs) cells are activated for 24 hours. Supernatant of each 
well is collected and cytokine measurements are done with the Luminex system (Austin, TX). 
 
7. Statistical analysis 
Statistical analyses are conducted with the Graphpad Prism4 program by using the paired, 
two-tailed student t-test. P-values less than 0,05 are considered as significant. *P<0,05, 
**P<0,01, ***P<0,001 
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8. Aryl hydrocarbon receptor in DC subsets 
The Aryl hydrocarbon receptor (AhR) has a longstanding research interest in our lab. 
Platzer and Richter et al. published data about the role of this molecule in 
Langerhans cell development from CD34+ hematopoietic progentitor cells. They 
found out that the activation of AhR by AhR-ligand VAF347 leads to an arrest of LC 
development in a monocytic stage due to an inhibition of up-regulation of the crucial 
LC transcription factor PU.1. They also investigated AhR levels in different myeloid 
cell subsets by western blot and found that LCs express highest levels of AhR 
followed by monocytes, whereas granulocytes and the progenitor cells itself express 
only very low to undetectable levels of AhR protein. (Platzer et al. 2009) The first part 
of this project is to further elucidate the function of this protein in different dendritic 
cell subsets and in vivo in human skin. 
8.1. Generation of dendritic cell subsets: differentiation and purity 
To generate Langerhans cells (LCs) and interstitial dendritic cells (intDCs) we isolate 
CD34 positive hematopoietic progenitor cells from cord blood with a positive 
selection kit from EasySep®. After an expansion period of 3-7 days in the presence 
of Flt3L, SCF and TPO the cells are set up in LC mix (GM-CSF; Flt3 ligand, SCF, 
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TNFα and TGF-β1) for 7 days and cluster purified over a PBS gradient to enrich LCs. 
To set up intDCs, cells differentiate for 5 days in the LC mix without TGF-β1 and are 
then washed and transferred to RPMI medium with GM-CSF and IL4 for another 5 
days. Monocyte-derived LCs (moLCs) and DCs (moDCs) are differentiated from 
CD14 positive monocytes isolated from peripheral blood with a positive selection kit 
from Miltenyi Biotec®. While moDCs need GM-CSF and IL4 for 4 days, moLCs are 
generated in the presence of GM-CSF and TGF-β1 on Delta-1 coated plates for 4 
days. To ensure differentiation efficiency and purity of the dendritic cell subsets we 
perform a FACS staining for CD11b and CD1a (intDCs and moDCs) and CD1a and 
Langerin (LCs and moLCs). Figure 12A and B show an overview of the experimental 
set up of the differentiation methods. The representative FACS blots depicted in 
figure 12C show the gating strategy for the DC subsets used in this project. The 
average purity for moDCs and IntDCs is between 80-95%, for LCs around 60-80% 
and for moLCs around 50-70% under optimal conditions. 
 
8.2.  Aryl hydrocarbon receptor is most prominently expressed in LCs and moDCs 
followed by intDCs and moLCs 
Dendritic cell subsets are generated according to the generation methods described 
in chapter 8.1. Western blot samples are prepared according to the cell number. 
Figure 13 shows a representative western blot of the dendritic cell subsets and figure 
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2B shows the statistical quantification of three independent donors. From these 
results it becomes obvious that LCs express the highest levels of AhR followed by 
and moDCs and intDCs whereas moLCs only express low levels of the protein. 
 
8.3.  Cytoplasmic localization of AhR and subsequent nuclear translocation upon 
NiSO4 activation 
As we have now shown, that AhR is present in DC subsets, we further want to 
investigate the cellular localization of the protein. In addition to this we want to 
analyze the behavior of the AhR upon cellular stimulation with contact hypersensitivity 
inducing agents such as the contact irritant (SDS) or contact sensitizer (NiSO4) to see 
whether there are potential differences in the protein reaction in these two different 
stimuli. To address this question we generate moLCs and LCs according to the steps 
described in chapter 8.1. After the differentiation period the cells are activated with 
SDS and NiSO4 for 24 hours. On the next day the cells are fixed and stained for AhR 
and CD1a with a nuclear counterstaining with dapi. Figure 14 shows representative 
immunfluoresence pictures of moLCs without stimulation (A), SDS (B) and NiSO4 (C) 
treatment. These results depict, that about 75% of the cells show a cytoplasmic AhR 
staining in immature moLCs. Preliminary data suggest that upon SDS activation AhR 
translocates to the nucleus in about 20% of the cells whereas 60% of the cells have 
AhR in both, the cytoplasm and nucleus. NiSO4 activation on the other hand leads to 
a strong nuclear translocation of AhR with about 90% of the cells showing a strong 
and exclusively nuclear staining for AhR as presented by the statistical analysis 
shown in figure 14 D. Figure 15 shows the results of the same experiment performed 
on LCs. The quantification of three independent donors is shown in part D of figure 
15. LCs show a similar outcome, namely the predominantly cytoplasmic localization 
of the protein (~90% of the cells) in the immature state. Upon SDS activation of the 
cells AhR translocates to the nucleus in approximately 10% of the cells and 20% 
show a cellular distribution between the cytoplasm and the nucleus. However, NiSO4 
is a stronger inducer of the nuclear translocation of the protein, which is also reflected 
in the statistical analysis. The quantification shows that over 60% of the cells are 
strongly positive for nuclear AhR staining while the rest of the cells show AhR signal 
in both, the cytoplasm and the nucleus. 
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8.4.  AhR is present in the nucleus of in-vivo LCs from human skin 
As we have confirmed the expression of AhR in in-vitro generated DC subsets and 
showed its nuclear translocation upon NiSO4 activation we want to shed further light 
on the in-vivo situation of LCs in human skin. To accomplish this question we prepare 
cryofrozen sections of human skin grafts activated with SDS or NiSO4 over night or 
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without treatment as a control. After blocking the skin sections, we stain AhR shown 
in green and CD1a shown in red. In the end we counterstain with Dapi shown in blue 
to visualize the nuclei. Figure 16 shows representative immunfluoresence pictures. In 
(A) we see the untreated cells. The white arrow points towards a Langerhans cell in 
the epidermis, which is positive for AhR in the cytoplasm and the nucleus. Part (B) 
and (C) of figure 16 show representative pictures of the treated conditions, SDS and 
NiSO4 respectively.  
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So far we conclude, that AhR is present in the nucleus of LCs in human skin no matter 
whether we activated the skin or not. Further experiments are needed to clarify whether there 
is a shift towards a more prominent nuclear staining upon activation with SDS or NiSO4.  
 
9. Monocyte-derived LCs treated with AhR ligands 
Susanne Richter has already extensively investigated CD34 positive derived LCs, which 
were generated in the presence of AhR ligands FICZ and VAF347. To sum up her findings, 
what she saw was that LCs with an activated AhR show a diminished differentiation capacity 
and a decreased maturation potential. Upon FICZ- or VAF347-induced AhR activation while 
the differentiation period, LCs had an increased CD14 expression and lower basal levels of 
AhR expression. When these cells were subsequently activated with PGN, AhR upregulation 
was decreased and the typical maturation potential of LCs was down-regulated. In more 
detail the up-regulation of maturation markers was decreased, the secretion of cytokines 
declined and the induction of Th1+Th22 T helper cell induction was reduced (Richter 2010). 
As the literature regards these CD34 positive HSC derived LCs to resemble more the steady 
state LCs we also want to see how the inflammatory LCs behave in the same context. 
Therefore the second part of the project focuses on the generation of moLCs from peripheral 
blood monocytes in the presence of two different AhR ligands and takes a closer look on the 
differentiation capacity and the maturation potential of these cells. 
9.1. MoLCs generated in the presence of AhR ligand FICZ show a tendency 
towards more Langerin/CD1a double positive cells 
To address the question whether moLCs generated in the presence of AhR ligand 
FICZ show differences in differentiation and maturation, we differentiate moLCs from 
CD14 positive peripheral blood monocytes with or without the addition of AhR ligand 
FICZ. After 4 days of differentiation the cells are analyzed by FACS staining to 
investigate the surface marker expression profile. In addition to this cells are activated 
with lipopolysaccharide (LPS) and peptidoglycan (PGN) for 24 hours to investigate 
their maturation potential. On the next day the cellular supernatant is analyzed for 
cytokine levels and the cells are again analyzed by FACS staining. We also prepare 
western blot samples to see whether AhR translocates to the nucleus and RelB gets 
activated upon maturation of the cells.  
Results 
51 
 
Figure 17 shows data acquired by these experiments. In Figure 17A we see a 
representative FACS blot of DMSO versus FICZ treated moLCs. What we can see is 
a tendency towards more CD1a/Langerin double positive cells in FICZ treated cells, 
which can also be seen in the diagram summing up the percentages of six 
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independent donors. In addition to this we can also see a decrease in E-cadherin 
expression and a slight increase in CD11b expression whereas CD14 gets slightly 
down-regulated. Figure 17B underlines the above described effects by the statistical 
quantification of six independent donors. The results show a significant increase in 
Langerin and CD11b positive cells. CD1a positive cells increase, whereas E-cadherin 
positive cells significantly decrease and CD14 positive cells slightly decrease in FICZ 
treated cells. Figure 17C, D and E show the results of the maturation FACS analysis. 
We focus on the well established maturation marker of dendritic cells, namely CD80, 
CD83, CD86, CD40 and HLADR. In the histogram overlays of DMSO versus FICZ 
treated cells of the mean fluorescent intensity from the maturation markers gated on 
moLCs we see no difference upon PGN activation but LPS activation leads to slight 
decrease of CD80, CD86 and CD83 whereas CD40 and HLADR show a slight drift 
towards higher expression. If we now focus on Figure 17D for PGN and 17E for LPS 
activated cells, we see that this trend is also reflected in the statistical analysis 
throughout all six independent donors. PGN activation shows no change in activation 
marker expression between DMSO and FICZ treated moLCs. However, LPS on the 
other hand shows a significant down-regulation of maturation marker expression of 
CD86, CD83 and CD80 and a tendency towards a slight increase of CD40 and 
HLADR expression. Figure 18 presents the data of the maturation analysis by 
western blot and cytokine measurements. Figure 18A shows a representative western 
blot which shows a decrease in AhR signal in the DMSO and FICZ treated cells in the 
unstimulated and stimulated conditions. AhR down-regulation in the unstimulated 
condition is most likely due to slight pre-activation of the cells because of physical 
handling. RelB gets up-regulated upon activation stimuli LPS and PGN in both 
generation models. Figure 18B shows the statistical quantification analysis from four 
independent donors. The AhR/actin ratio decreases in LPS and PGN stimulated 
conditions when compared to the 0h time point. The RelB/actin ratio increases upon 
stimulation. Figure 18C and D show the results of the cytokine measurements of LPS 
and PGN activated cells respectively. What we can conclude from these data is that 
LPS treatment of FICZ treated cells tends to lead to a higher cytokine secretion with 
the exception of IL10. PGN activation of FICZ treated cells on the other hand leads to 
a down-regulation of cytokines with the exception of IL6 and Il12p40. 
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To sum up the results we state that FICZ treated monocytes tend to generate more 
moLCs, which show lower levels of E-cadherin and upon LPS, but not PGN 
activation, show a decreased maturation potential. In addition to this we see a 
decrease in AhR protein levels after stimulation in both conditions which is evidence 
of a nuclear translocation upon activation. RelB also gets activated upon stimulation 
without any difference between FICZ treated and control cells. 
 
Results 
54 
9.2. MoLCs generated in the presence of AhR ligand VAF347 tend to generate more 
LCs but show no significant change in maturation potential  
While FICZ is a physiologic, endogenous AhR ligand, VAF347 is an exogenous 
pharmaceutically engineered AhR ligand. As it becomes more and more obvious that 
endogenous and exogenous AhR ligands have different effects on cellular behavior, 
we next asked the question whether FICZ and VAF347 have similar effects on moLC 
differentiation and maturation. Therefore we generate moLCs in the presence of 
VAF347 and perform the same experimental analysis as with the moLCs generated in 
the presence of FICZ (see chapter 9.1.). Figure 19 shows the results of the FACS 
analysis of differentiation and maturation of moLCs. Part A of figure 19 shows a 
representative FACS blot of differentiated cells. Compared to control cells, VAF347-
treated cells show a tendency towards more CD1a/Langerin double positive cells. 
VAF347 treated cells display a slightly reduced expression of E-cadherin and a 
slightly increased CD11b expression. The statistical analysis of three independent 
donors depicted in figure 19B also reflects this trend: CD1a/Langerin double positive 
cells increase in the presence of VAF347. Langerin, CD1a and CD11b mean 
fluorescent intensities (MFI) are slightly higher in VAF347-treated cells, whereas the 
E-cadherin and CD14 MFI tends to slightly decrease. Figure 19C shows 
representative histogram overlays of the maturation markers from gated moLCs of 
DMSO versus VAF347 treated cells. We see a tendency of higher MFI levels of 
CD86, CD80 and CD83 whereas CD40 and HLADR show a slightly lower expression. 
The statistical analysis of three independent donors shows that there is only a 
significant change for CD86. Regarding these results we conclude that there are only 
minor effects on the maturation potential of VAF347 treated moLCs. Figure 20A 
shows a representative western blot of PGN activation. We can see that AhR protein 
signal decreases in FICZ and VAF347 treated cells in both, without and PGN 
activated conditions. RelB on the other hand is activated upon PGN maturation in 
DMSO, FICZ and VAF347 treated cells. The statistical analysis of the quantification of 
four independent donors shown in figure 20B reflects the same trends. In figure 20C 
we see the diagrams of the cytokine secretion analysis of the culture supernatant 
after PGN activation. Preliminary data of two independent donors suggest that 
VAF347-generated cells tend to produce slightly more IL10, IL8 and IL12p40 whereas 
IL6 and TNFα show no change. IL1β tends to be secreted to a lesser extent.  
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To sum up, VAF347 shows similar effects as FICZ during the differentiation process 
of moLCs. There is a tendency towards increased expression of LC markers like 
Langerin and CD1a whereas E-cadherin is decreased. Regarding the data of the 
maturation analysis we conclude that there is no significant change in the maturation 
of VAF347 treated moLCs compared to control cells. 
 
9.3. MoLCs generated in the presence of FICZ and increasing concentrations of 
TGF-β1 show a decrease in E-cadherin expression 
As we have seen an effect of AhR ligands on the generation of moLCs we ask the 
question whether this effect is dependent on TGF-β1, the crucial cytokine for LC 
differentiation. To examine this question we generate moLCs in the presence of FICZ 
with increasing concentrations of TGF-β1 (0, 1, 3,3, 5, 15 and 30ng). Figure 21 
presents the data gained by these experiments. In figure 21A we see the statistical 
quantification of two independent donors which show that CD1a/E-cadherin double 
positive cells are dramatically decreased in FICZ treatedcells over the whole TGF-β1 
concentration range. This can also be seen in the E-cadherin MFI gated on living 
cells. In figure 21B we see a representative FACS blot of CD1a versus Langerin of 
cells differentiated in the presence of DMSO or FICZ. The histogram shows the E-
cadherin MFI of CD1a/Langerin double positive gated cells. We see a drastic 
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decrease in E-cadherin signal which is also reflected in the E-cadherin MFI statistics 
of two independent donors. Finally in part C of figure 21 we see representative light 
microscope pictures of cells differentiated with or without TGF-β1 in the presence of 
DMSO or FICZ. It becomes obvious that FICZ treated cells generate more clusters in 
comparison to DMSO treated cells but they are smaller in size and less dense. From 
these results we can conclude that TGF-β1 is required to generate moLCs and that 
the AhR ligand effect on the E-cadherin expression of moLCs is independent of TGF-
β1 but strictly dependent on ligand activated AhR. 
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10. Effects of AhR on transcription profile and signaling in LCs 
Researchers from our lab have investigated the effect of AhR ligands in LC differentiation on 
the transcriptional level and found that VAF347 treatment impairs LC differentiation by 
inhibiting PU.1 up-regulation in a monocytic precursor form at an early differentiation state. 
We want to further shed light on the transcription factor profile after 7 days of culture to see 
whether AhR ligands also influence the transcriptional program at a later time point. What 
becomes clear from the current state of literature is that AhR signaling varies from cell-type 
to cell-type and is dependent on a multitude of endogenous and exogenous factors. Some 
papers point towards an involvement of p38 MAPK whereas others object to this and 
implicate JNK and ERK MAPK or NFκB cooperation. We want to further shed light on the 
situation in LCs. Additionally we want to investigate RelB signaling in LCs and moLCs in 
response to NiSO4 and SDS to unravel potential similarities because this molecule as well 
has been implicated in AhR signaling (Vogel et al. 2007). 
 
10.1. Transcription factor profile of AhR ligand treated LCs shows no change 
in fully differentiated or activated LCs 
To further investigate how AhR ligands influence the generation of LCs we have 
analyzed samples (kindly provided by Susanne Richter) of LCs which were generated 
in the presence of FICZ or VAF347 AhR ligands. After 7 days of differentiation the 
cells are FACS sorted for CD1a/Langerin double positive cells. Western blot samples 
normalized to the cell number are prepared and the rest of the cells are activated with 
PGN for 24 hours. On the next day cells are harvested, counted and western blot 
samples are prepared normalized to cell numbers. The results in figure 22A show two 
representative Western Blots of differentiated LCs analyzed for the most prominent 
LC transcription factors, namely AhR, RelB, VDR, PU.1 and p65 (RelA). There is no 
change in transcription factor expression in AhR ligand treated LCs. The same is true 
for transcription factor levels after PGN maturation, which can be seen in figure 22B. 
Only PU.1 and AhR tend to be reduced in AhR ligand-treated cells due to AhR-ligand-
dependent blockage of PU.1 up-regulation (Platzer et al. 2009) and AhR activation 
through the ligands and the following protein degradation respectively. 
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10.2. AhR nuclear translocation is disabled by a JNK inhibitor while NFkB 
inhibition enforces the nuclear translocation 
While the functional steps of AhR activation have been unraveled, the signaling 
cascade which is triggered to translocate AhR into the nucleus is still unknown. In 
previous experiments (see chapter 8.3.) we have encountered strong nuclear AhR 
translocation upon NiSO4 activation. In the literature there have been publications 
indicating that NiSO4 leads to the phosphorylation of p38 MAP kinase (Arrighi et al. 
2001; Boisleve et al. 2005; Miyazawa et al. 2007). Therefore we want to further 
investigate the importance of the p38 signaling cascade in LC maturation. We 
specifically focus on compounds which either inhibit p38 signaling (SB203580-> ERK 
inhibitor), β-catenin/Wnt siganling (SB216763 -> GSK3 inhibitor), JNK signaling 
(SP600125) or NFkB (RelA) signaling (SN-50). To accomplish this question we 
generate LCs from CD34+ hematopoietic progenitor cells. After 7 days of culture we 
purify the cell clusters and pre-incubate them with the corresponding inhibitors for 1 
hour before we activate the cells over night with PGN. On the next day we prepare 
western blot samples to analyze AhR protein levels in inhibitor-treated, activated 
cells. Figure 23A shows the experimental set up. In figure 23B we see a 
representative western blot, which shows a decrease in AhR protein signal in the 
without (wo) and PGN-activated conditions, which is most likely due to AhR activation 
through physical handling. Nevertheless it becomes obvious that the SP inhibitor 
Results 
60 
disables the nuclear translocation of AhR upon PGN activation because the signal 
does not decrease in PGN activated cells. SN-50, an NFkB (RelA) inhibitor on the 
contrary significantly enhances nuclear translocation of AhR upon PGN activation. 
P38 MAPK inhibitor on the contrary does not interfere with nuclear translocation and 
for the β-catenin/Wnt inhibitor the results are varying but overall shows no consistent 
inhibition of the nuclear translocation of AhR as can be seen in the statistical analysis 
of three independent donors (figure 23C). 
 
 
10.3. RelB, an important factor in LC maturation, shows a similar activation 
pattern upon SDS and NiSO4 treatment 
Previous work from our lab has shown the importance of RelB during LC maturation 
as a regulator to prevent hyper-activation of LCs.(Jorgl et al. 2007) As this regulator is 
very important especially in LC maturation we want to investigate the RelB levels in 
different DC subsets. For this purpose we generate moLCs and moDCs from CD14+ 
peripheral blood monocytes and intDCs and LCs from CD34+ hematopoietic 
progenitor. After differentiation the cells are analyzed by FACS to ensure 
differentiation efficiency and purity of the cells. Western Blot samples are prepared 
normalized to the cell number. Figure 24A shows a representative western blot 
displaying the highest RelB levels in moDCs while moLCs, LCs and intDCs express 
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similarly lower levels of RelB. These results are also reflected in the statistical 
analysis of the quantification of 3 independent donors shown in figure 24B. 
 
 
10.4. Immature moLCs and LCs show a cytoplasmic cellular localization of 
RelB which translocates to the nucleus upon NiSO4 activation 
With our previous experiment we could show that RelB is expressed in all dendritic 
cell subsets. For AhR we could show that the stimulation with contact sensitizer 
(NiSO4) or contact irritant (SDS) in moLCs and LCs leads to a differential nuclear 
translocation of the protein. As a next step we want to elucidate whether RelB reacts 
in a similar way. After generating moLCs and LCs, we activate them for 24 hours with 
SDS and NiSO4. On the next day we fix the cells and stain them for RelB shown in 
green, CD1a shown in red and the nucleus shown in blue. Figure 25 shows 
representative pictures of the stainings performed in moLCs. The inactivated 
condition (wo) is presented in A, which shows a cytoplasmic distribution for RelB. Part 
B and C show the SDS and NiSO4 activated conditions respectively. These results 
point out that only the NiSO4 activation leads to a nuclear translocation of RelB, while 
SDS treatment has no impact on RelB activation.  
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Figure 26 presents representative data of the same experiments conducted in LCs 
(pictures kindly provided by Rene Köffel). Concerning the RelB activation and nuclear 
translocation, LCs show the same results like moLCs. Taken together, these results 
are quite interesting, also in relation to the similar behavior of AhR in the same 
context. 
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10.5. NiSO4 activation of DC subsets leads to nuclear translocation of AhR 
and activation of RelB 
So far we could show that AhR and RelB are expressed in all dendritic cell subsets 
investigated. In addition to this we could proof that in moLCs and LCs, NiSO4 
activation leads to a potent nuclear translocation of both proteins. With our next 
experiment we want to investigate whether this nuclear translocation is also 
detectable with the western blot method and whether this effect is equally pronounced 
in all DC subsets to further underline its importance. We generate moLCs, moDCs, 
intDCs and LCs. After the differentiation period the cells are activated with NiSO4 for 
24 hours and on the next day western blot samples are prepared according to the cell 
number. Preliminary results are depicted in figure 27, where A shows a representative 
western blot and B the corresponding quantification of the results. If we draw our 
attention to the western blot we can see that NiSO4 activation leads to a dramatic 
decrease of AhR signal which is due to the nuclear translocation of the protein and its 
subsequent degradation in the cytoplasm. We can also see that the RelB signal 
slightly increases in the NiSO4 treated conditions throughout all DC subsets, although 
LCs do not show such a pronounced effect, which could be due to a pre-activated 
state of the cells in the wo condition because of physical handling. The trends we see 
in the western blot are also underlined by the quantification of the two western blots 
from one donor shown in figure 27B. Priliminary data show that the AhR/actin ratio 
decreases upon NiSO4 activation in all DC subsets, whereas the RelB/actin ratio 
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increases with activation with the exception of LCs due to the above mentioned pre-
activated state of the cells. 
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11. p100ΔN infected LCs underline potential interplay between AhR 
and RelB 
As we have discovered an interesting similarity in the NiSO4 maturation pattern of AhR and 
RelB protein in LCs we further ask the question to which extent these two proteins interact 
during this process. There are groups which have already reported about an AhR/RelB 
heterodimer (Vogel and Matsumura 2009; Vogel et al. 2007). This AhR/NFκB heterodimer 
was found to bind to newly discovered AhR/NFκB DNA recognition sites in promoters of 
genes associated with immune reactions such as chemokines (Vogel et al. 2011; Vogel et al. 
2007). Our LC generation protocol poses an ideal experimental investigation system, as we 
could already show, that these cells express high levels of AhR and RelB. In addition to this 
NiSO4 maturation causes the activation of both proteins and leads to nuclear translocation. 
Moreover we have seen that our LCs produce high amounts of IL8 upon maturation (Nighat 
Yasmin, unpublished data), which is indeed interesting with regard to a recent report 
implicating the IL8 promoter to harbor such newly described NFκB/AhR heterodimer binding 
sites (Vogel et al. 2011). Furthermore we have the system of retroviral infection well 
established in our lab and are therefore able to transduce these cells with a retroviral 
construct, namely the pBMNp100ΔN construct. Figure 28 B and C illustrates the construct in 
use. It consists of a p100 protein version which lacks ankyrin repeats. These repeats in turn 
are crucial for further proteosomal degradation of the p100 precursor into the p52 protein. 
Only the processed p52 form is able to undergo nuclear translocation. The p100ΔN construct 
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leads to a sequestration of RelB/p100 heterodimers in the cytoplasm. To investigate the 
question of a potential interplay between AhR and RelB in our LC system we infect CD34 
positive hematopoietic progenitor cells with the pBMNp100ΔN construct. The experimental 
set up is outlined in figure 28A. The infected and expanded progenitor cells are then set up to 
differentiate into LCs. After the differentiation period the LC clusters are purified over a PBS 
gradient and set up for an activation time course with NiSO4 at 3, 6 and 24 hours. The culture 
supernatant is analyzed for cytokine secretion and the cells are analyzed by FACS staining. 
Total cellular RNA is isolated to assess levels of IL8 and Cyp1a1 mRNA to investigate the 
induction of gene expression upon maturation. In addition to this cells are immunostained for 
RelB, to proof the effectiveness of the transduced construct, and for AhR to see whether 
nuclear translocation still takes place when RelB is kept in the cytoplasm. 
 
11.1. p100ΔN transduced LCs show no change in differentiation and 
maturation 
Figure 16 shows data from the FACS staining after LC maturation. In Figure 29A we 
see a representative FACS diagramm. The infection rate is around 50-70% for both 
the construct and the empty vector control. Cells are gated for GFP positive cells 
(marked red). In the control cells (first two lines), LC generation efficiency is around 
50-60% and shows no significant change in the pBMNp100ΔN transduced cells. This 
can also be seen in the diagram depicting CD1a/Langerin double positive cells of 
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three independent donors. Upon maturation with NiSO4, the cells loose Langerin and 
CD1a expression and up-regulate CD83 (Figure 29A, last row), CD40, CD80 and 
HLADR (Figure 29B). Figure 29B shows representative histogram overlays of the 
maturation markers gated on LCs. While CD40 and CD80 show no difference in 
activation state CD83 and HLADR tend to be slightly less expressed compared to the 
empty control vector. CD40 and HLADR show slightly pre-activated cells in the 
inactivated condition, whereas CD80 and CD83 do not show this effect. Nevertheless 
these changes are not significant and taken together there seems to be no effect in 
maturation potential regarding the expression profile of activation markers.  
 
11.2. AhR nuclear translocation upon maturation is not inhibited by RelB 
cytoplasmic sequestration 
Figure 30 and 31 show representative pictures of the immunostainings for RelB and 
AhR respectively. Cells are fixed on adhesive slides and stained for RelB or AhR, 
shown in red. CD1a staining is done to identify LCs and is shown in white. Nuclei are 
counterstained with dapi and shown in blue. Infected cells can be distinguished from 
normal cells through the GFP signal, as the transduced vectors have a GFP epitope 
to track the constructs. In figure 30 we can see the RelB staining of construct or 
empty transduced cells from inactivated and NiSO4 activated cells. As already 
previously shown inactivated cells show a cytoplasmic localization of the protein, 
indicated with white arrows in Figure 30A and C. What becomes obvious from the 
pictures in figure 30B and C is that RelB nuclear translocation upon maturation is only 
completely blocked in strongly pBMNp100ΔN transduced cells, indicated by the white 
arrows, whereas slightly transduced cells (indicated by the yellow arrows) and empty 
vector control transduced cells show a normal RelB nuclear translocation upon 
stimulation. The immunostaining of AhR of transduced LCs is shown in figure 31. Part 
A and B of figure 31 show the pictures of the empty vector transduced cells without 
(A) and with NiSO4 activation (B). Upon maturation we see a nuclear signal for AhR. 
The same is true for the pBMNp100ΔN transduced cells. To sum up we can state that 
RelB sequestration in the cytoplasm does not inhibit AhR nuclear translocation upon 
NiSO4 activation which in turn indicates that AhR and RelB proteins independently 
translocate to the nucleus. 
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11.3. IL8 secretion and il8 mRNA production are increased in p100ΔN 
transduced LCs 
Figure 32A shows the cytokine levels of after a time course of NiSO4 activation. IL8 
cytokine secretion tends to be increased in the pBMNp100ΔN transduced cells after 3 
hours. This effect is leveling out after 6 to 24 hours. These data indicate that RelB 
inhibition has a very immediate effect on the IL8 secretion. Results from the pPCR 
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analysis for cyp1a1 are not shown here as we have not seen any detectable induction 
of the gene. This is a further indication that AhR, upon NiSO4 activation indeed 
translocates to the nucleus but does not bind to commonly known XREs, including the 
Cyp proteins, but has other target sites to exert different signals. The data from the il8 
gene qPCR are presented in figure32B. The diagram shows the representative data 
of one experiment of the x-fold induction change in il8 mRNA production normalized 
to the house keeping gene gapdh. Preliminary data point towards an increased il8 
mRNA production after 3 hours of NiSO4 induction. 
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Discussion 
AhR and RelB levels in DC subsets: In our lab we showed before that the highest AhR 
expression in the myeloid cell lineages are found in LCs followed by monocytes whereas 
granulocytes and neutrophils show only basal to no AhR levels (Platzer et al. 2009). 
Therefore we further concluded that AhR is characteristically expressed in dendritic cells and 
might have an essential role in these cell types. In our studies we investigated various 
dendritic cell subsets for their basal AhR levels and found that CD34 derived LCs and 
monocyte derived DCs express the highest levels followed by interstitial DCs. Inflammatory 
monocyte derived LCs on the other hand only express low levels of AhR. Additionally we 
analyzed RelB levels in these DC subsets and could show that moDCs express the highest 
RelB levels followed by LCs, moLCs and intDCs. To sum up moDC are the DC subtype with 
the highest levels of AhR and RelB followed by LCs. Although we crossed out experiments 
with generation rates less than 50% purity, the obstacle of these experiments is that purity 
rates vary between the different donors and therefore protein levels have to be interpreted 
with caution. The best analysis method would be to sort the generated cells for cell lineage 
specific markers to be sure to analyze a homogenous population. Nevertheless the cellular 
stress from the cell sorting process could interfere with protein levels therefore we stick to the 
conventional method of FACS purity check and immediate western blot sample preparation 
to preserve natural protein levels from inactivated cells. Indeed it is interesting that LCs, 
which are situated in the epidermis and are continuously in contact with the environment, 
express the highest levels of AhR and RelB, which in turn are two proteins involved in 
immune-regulatory processes. One can speculate that DC subtypes which are constantly 
exposed to environmental stress need to have a mechanism to regulate immune responses 
to establish a certain tolerance to prevent immune overreaction. DC subsets which are not 
constantly exposed to the environment (e.g. intDCs) or arise under inflammatory conditions 
(moLCs) express lower levels of these immune regulatory proteins. 
 
AhR and RelB localization after NiSO4 activation in LCs: LC activation with the chemical 
sensitizer NiSO4 or the chemical irritant SDS induces a divergent cellular localization pattern 
of AhR and RelB. By using immuno-histochemistry we were able to show that only NiSO4 
induces a strong nuclear translocation of AhR in LCs and moLCs. SDS in comparison only 
slightly induced nuclear translocation of AhR although moLCs tend to have more nuclear 
AhR upon SDS treatment compared to LCs. Our protein level analysis of AhR in DC subsets 
revealed that moLCs express very low levels of basal AhR, which could be the reason why 
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SDS is able to slightly translocate this AhR whereas the high basal levels of AhR in LCs 
seem to be less susceptible to SDS-induced nuclear translocation. Apart from this it has to 
be mentioned that also physical handling of the cells can lead to AhR activation and 
translocation into the nucleus although this activation is not as intense as the NiSO4 
activation.  
We did the same experiments for RelB and could show that upon NiSO4 but not SDS 
activation RelB translocates into the nucleus in LCs and moLCs. Therefore we speculate that 
AhR translocation upon activation could be an indicator which distinguishes reactions to 
contact sensitizers to those from contact irritants. Nevertheless further experiments are 
needed to confirm this hypothesis. It would be interesting to compare immune responses of 
AhR knockout mice to NiSO4 and SDS in contact hypersensitivity reactions on the skin, to 
see whether AhR in epidermal LCs really plays a crucial role in the induction of an 
appropriate immune response to these chemicals.  
Preliminary data from western blot analysis of different DC subsets for AhR and RelB upon 
NiSO4 treatment showed that all DC subtypes harbor the same cellular mechanism in 
response to NiSO4. AhR activation and therefore decrease in signal takes place in all DC 
subsets just as RelB gets up-regulated in response to NiSO4 stimulation. Therefore we 
assume that all DC subtypes react in the same way to NiSO4 treatment although the basal 
levels of the proteins determine the strength of the reaction. Additionally it is interesting that 
both, AhR and RelB, are strongly translocated to the nucleus of NiSO4 stimulated LCs 
whereas SDS treatment does not lead to this strong nuclear co-localization as shown with 
immunostainings. This could imply a potential interplay between AhR and RelB in the cellular 
immune reaction towards chemical sensitizers. 
 
AhR in ex-vivo human skin: So far we could show that in in-vitro generated LCs AhR is 
cytoplasmically located and only translocates into the nucleus upon activation signals. To 
elucidate the in-vivo situation we stained AhR in human skin explants. What we have 
observed so far does not reflect the findings on in-vitro LCs. AhR seems to be in the nucleus 
in epidermal LCs independently of the activation state of the cells. Preliminary data imply that 
activation stimuli lead to a more intense and exclusively nuclear signal of AhR. Nevertheless 
for this assumption more donors have to be analyzed. Aside from this the basic nuclear 
localization of AhR in epidermal LCs can furthermore be explained by the fact that FICZ, an 
AhR agonist, is constitutively present in the skin. Through UV irradiation tryptophan gets 
metabolized to FICZ and is saturated in the epidermis (Fritsche et al. 2007). Constant AhR 
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activation through this endogenous physiologic ligand could explain constant activation and 
nuclear AhR localization in human skin LCs. However the interpretation of this finding is 
demanding as FICZ has been reported to worsen autoimmune diseases in a mouse EAE 
model and having a rather immune-stimulatory than an immune-repressive function 
(Quintana et al. 2008; Veldhoen et al. 2008). One possible model could be that the constant 
but short-lived AhR activation in the skin renders LCs less responsive to other environmental 
AhR ligands, thereby constituting a higher activation threshold in this cell type. Another 
possibility is that ligand activated AhR needs other inflammatory signals to properly induce 
immune reactions. It is also possible that the continuous AhR activation by the endogenous 
physiologic ligand FICZ impairs LC maturation so that T-cells cannot be properly activated 
and are therefore cleared or the balance shifts towards T-reg differentiation (Quintana et al. 
2008; Veldhoen et al. 2008).  
A possible future experiment could be to determine which influence light has on the proper 
immune reaction to contact hyper sensitivity reagents such as NiSO4. As a model one could 
use wild-type and AhR knock-out mice which are kept exclusively in the dark. First one would 
have to show that FICZ levels are depleted in the skin of mice which are kept in the dark. 
Second of all one would have to compare the immune reactions to NiSO4 and SDS in wild-
type and AhR knock-out mice and see whether a potential phenotype can be reversed by the 
application of light and the subsequent generation of AhR ligand FICZ.  
 
moLCs treated with AhR ligands FICZ and VAF347: FICZ is a physiologic endogenous high 
affinity ligand of AhR. After 4 days of differentiation of moLCs in the presence of FICZ we 
observed more Langerin/CD1a double positive cells. In more detail Langerin, CD1a and 
CD11b marker expression was increased whereas E-cadherin expression was significantly 
decreased. CD14 on the other hand was not influenced by AhR ligand FICZ. When moLCs 
were generated in the presence of the exogenous ligand VAF347 we observed similar 
trends. The MFI values of Langerin, CD1a and CD11b were increased as was the 
percentage of Langerin/CD1a double positive cells. E-cadherin MFI was decreased and 
CD14 expression was not influenced to a great extent.  
These findings are interesting with regard to the findings in LCs because AhR ligands seem 
to influence steady state LCs and inflammatory moLCs in a different way. In our lab it has 
been shown that LC differentiation in the presence of VAF347 is inhibited at a monocytic 
precursor state with elevated CD14 levels (Platzer et al. 2009; Richter 2010). Our findings 
show that AhR in these two LC subsets responds differentially to the same AhR ligands. A 
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possible explanation for this phenomenon could be the different basal levels of AhR in these 
two cell types and also makes sense with regard to their physiologic role. While steady-state 
LCs have to set up a complex tolerance system in the skin, inflammatory moLCs are only 
recruited in response to danger signals and ongoing inflammation with the purpose to clear 
the infection rather than induce tolerance. Monocytes recruited to the place of infection 
differentitate into moLCs. It could be that the presence of AhR ligands (e.g. FICZ) or 
potentially harmful environmental compounds (e.g. TCDD) increase the capacity of 
monocytes to differentiate into moLCs in an AhR-dependent manner to help clear the 
infection more rapidly. 
Furthermore we have analyzed the maturation potential of moLCs generated in the presence 
of AhR ligand FICZ. We have activated the cells with two different activation stimuli, namely 
Lipopolysaccharide (LPS) and Peptidoglycan (PGN). LPS signals through the TLR4 receptor 
and needs additional proteins for proper signal transduction such as lipopolysaccharide 
binding protein (LBP), CD14 receptor and MD-2. TLR4 levels on our in-vitro LCs are known 
to be very low and therefore LPS is considered a weak stimulus. PGN on the other hand can 
be recognized by CD14 (Dziarski et al. 1998), TLR2 (controversial) (Dziarski and Gupta 
2005; Travassos et al. 2004), nucleotide-binding oligodimerization domain-containing 
proteins (NODs) (Franchi et al. 2006) and PGN-recognition proteins (PGRPs) (Yoshida et al. 
1996). We and others could show that TLR2 is expressed on in-vitro generated LCs and 
therefore PGN acts as strong activation stimulus (Flacher et al. 2006; Jurkin et al. 2010; 
Renn et al. 2006; Rozis et al. 2008).  
Interestingly our data are not reflecting this typical characterization. We have observed that 
LPS stimulation of FICZ treated moLCs leads to a slightly reduced expression of co-
stimulatory molecules. PGN treatment on the other hand did not influence this expression. 
Same was true for cytokines as LPS tends to increase levels of IL1β, Il6, IL8 and TNFα 
whereas IL10 is slightly decreased and IL12p40 is not influenced. PGN on the other hand 
lead to an overall reduction of cytokine levels with the exception of IL8 and IL12p40 which 
were not changed. Additionally basal levels of cytokines without stimuli seemed to be slightly 
induced in FICZ treated cells. It is possible that activated AhR somehow primes cytokine 
promoters for transcription and facilitates their transcriptional control as has been implicated 
before in other models (DiNatale et al. 2010).  
We further analyzed the AhR activation in DMSO versus FICZ treated moLCs upon LPS and 
PGN stimulation. We could show that AhR is activated to the same extent in both conditions 
even in the absence of stimulus. This can be explained by physical handling of the cells 
leading to stress which can ultimately induce activation.  
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VAF347 treatment during moLC differentiation led to slightly different effects compared to 
FICZ treated moLCs. The strong stimulus PGN applied to VAF347 treated cells only caused 
a weak and partial up-regulation of co-stimulatory molecules. CD40 and CD83 showed no 
changes whereas CD80 and CD86 were slightly up-regulated and HLADR actually tended to 
be down-regulated. Basal cytokine levels were generally slightly induced, again underlining 
the concept of promoter priming of activated AhR. The cytokine profile slightly differed from 
the results we have obtained for FICZ treated cells. Preliminary data showed that IL10, IL8 
and IL12p40 tend to be slightly induced whereas IL6 and TNFα were not affected and IL1β 
seemed to be slightly down-regulated. Activation studies showed that AhR in VAF347 treated 
cells is translocated to the nucleus in PGN activated and inactivated conditions to a similar 
extent. We would have expected that control LCs down-regulate AhR more extensively upon 
PGN activation compared to VAF347 treated cells. Furthermore the hypothesis would 
implicate that VAF347 treatment leads to a decreased AhR activation capacity due to 
continuous stimulation with AhR ligand. Nevertheless we could not see this trend as AhR 
levels in VAF347 treated cells were already very low before actual activation treatment. This 
shows that VAF347 is a strong agonistic AhR ligand. RelB on the other hand was nicely up-
regulated in PGN treated conditions reflecting the proper activation of the cells. 
In summary we found that AhR ligand treatment during moLC generation leads to an 
increased differentiation potential of moLCs. Upon activation of these cells the maturation 
process is only slightly decreased or left unchanged. Nevertheless it becomes clear that LPS 
and PGN stimulation have different effects on AhR ligand treated cells. For example PGN 
treatment of VAF347 cells leads to a slight tendency towards increased co-stimulatory 
molecule expression and slightly induced cytokine production. LPS treatment of VAF347 
treated cells leaves the co-stimulatory molecule expression unchanged and only slightly 
reduces cytokine production. LPS and PGN activation of FICZ treated cells shows that the 
weaker LPS stimulation leads to a decreased co-stimulatory molecule expression profile but 
an increased cytokine production whereas PGN activation leaves maturation overall 
unchanged. These results confirm that AhR function in maturation depends on the stimulus 
present as has already been proposed by (Richter 2010). Nevertheless there are only small 
changes therefore we reason the effect of AhR ligands on maturation of moLCs is negligible 
and does not have an in-vivo effect. 
 
TGF-β1 and FICZ-activated AhR interplay in moLCs: There have been studies investigating 
the signal interplay between AhR and TGF-β1. What becomes clear from the literature is that 
this interplay is highly tissue and cell-type specific. For example in a prostate epithelial cell 
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line it has been shown that TGF-β1 suppresses AhR-induced target gene expression via the 
inhibition of AhR expression and down-regulation of nuclear AhR in a SMAD4-dependent 
way. Interestingly, AhR signaling induced by TCDD does neither affect TGF-β1 regulated 
gene expression nor epithelial-to-mesenchymal transition (Starsichova et al. 2012). In 
another report Guo et al. showed that AhR represses TGF-β genes in an AhR-ligand-
independent way (Guo et al. 2004). Chang et al. observed that AhR deficient mouse 
fibroblasts proliferated slower than wild type fibroblasts and that this happened in an AhR-
ligand-independent way. In addition to this they reported that AhR-deficient fibroblast secret 
higher levels of TGF-β1 and have higher levels of activated SMAD4 and TGF-β1 mRNA 
(Chang et al. 2007). E-cadherin expression is a key hallmark of immature LCs. E-cadherin is 
responsible for the interaction with epithelial cells and keeps the epidermal dendritic LCs in a 
regular network in the skin. Strobl et al could show that TGF-β1 is essential for in-vitro 
generation of LCs from CD34 positive HSC. In culture these cells form clusters in a strictly 
TGF-β1 dependent way and express high levels of E-cadherin (Strobl et al. 1996). Upon 
activation Langerhans cells down-regulate E-cadherin and the clusters are loosened and 
broke down. This down-regulation of E-cadherin is essential for LC maturation because the 
cells need to leave the epidermis and migrate to the draining lymph node. Riedl et al could 
show that ligation of E-cadherin on immature LCs prevents them from acquiring a mature 
state. They further concluded that this constitutive E-cadherin-mediated suppression of LC 
maturation in the epidermis could prevent uncontrolled LC activation (Riedl et al. 2000). In 
our experiments we asked the question what effects FICZ-activated AhR might have on 
TGF-β1-dependent moLC generation. We found that FICZ treated moLCs, independent of 
TGF-β1 concentration, express lower levels of E-cadherin, while other TGF-β1-dependent 
LC typical markers such as CD1a or Langerin were not affected. Furthermore we have 
observed that typical LC cluster formation is disrupted in FICZ treated cells in a way that cells 
form more but smaller and less compact clusters. E-cadherin is a TGF-β1 target gene in LC 
differentiation and FICZ is an AhR ligand that is constitutively present due to UVB-irradiation-
dependent processing of tryphtophan to FICZ (Fritsche et al. 2007). LCs need to have 
mechanisms for potent tolerance induction because this cell type is constantly exposed to 
environmental influences. It has even been reported that LCs travel to the draining lymph 
node at a basal rate in steady-state conditions in the absence of danger signals to present 
self-antigen and induce tolerance (Steinman and Nussenzweig 2002). Therefore we 
speculate that LCs in FICZ-saturated epidermis are constitutively expressing lower levels of 
E-cadherin in an AhR-dependent way which renders them more motile. This effect could 
facilitate the semi-maturation of LCs in the absence of danger signals and therefore enables 
the generation of semi-activated LCs. This hypothesis needs further testing by FACS 
analysis of the maturation state and comparison between various AhR ligands. Interestingly 
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there are two groups linking E-cadherin to induction of tolerance. In more detail E-cadherin 
down-regulation leads to the activation of β-catenin/Wnt signaling which is implicated in 
tolerance induction (Fu and Jiang 2010; Manicassamy et al. 2010). It would be interesting to 
test in-vivo E-cadherin levels of LCs compared to other epithelial DC cell types. In addition it 
would also be interesting to compare E-cadherin levels of LCs from wild-type and AhR 
knock-out mice. Furthermore it would be interesting to investigate β-catenin/Wnt signaling in 
this process to further unravel a potential tolerance inducing mechanism in the skin immune 
system. 
 
Transcription factor profile in AhR ligand treated LCs: Platzer and Richter et al. investigated 
CD34 derived LCs for AhR ligand effects during early differentiation. They could show that 
VAF347 impairs LC differentiation from CD34+ HSC. Activated AhR inhibited PU.1 up-
regulation which is necessary for the differentiation of monocytes towards LCs (Platzer et al. 
2009). In our studies we further analyze the effect of AhR ligands on LCs regarding their 
transcription factor profile before and during PGN maturation. LCs which were generated in 
the presence of AhR ligands and analyzed after 7 days of differentiation showed no 
remarkable difference in transcription factor profiles of PU.1, p65, VDR, AhR or RelB. Only 
PU.1 and AhR were reduced in AhR ligand treated cells due the blockage of PU.1 up-
regulation (Platzer et al. 2009) and AhR activation through the ligands and the following 
protein degradation. Additionally PGN induced maturation did not lead to a change in 
transcription factor expression. These results are in line with the findings of Platzer and 
Richter et al because they further underline the early effect of AhR on transcription factors in 
progenitor cell differentiation rather than a late function in differentiated LCs or maturation 
process. 
 
AhR signaling in LCs: As described in the introduction there have been many - partly 
controversial - reports about the signaling cascades involved in AhR activation and 
subsequent nuclear translocation. P38 MAPK has been implicated in AhR activation by 
multiple groups. On the one hand it has been proposed that p38 MAPK phosphorylates the 
NES sequence of AhR protein at Ser-68 thereby inhibiting AhR nuclear export which leads to 
prolonged AhR signaling (Ikuta et al. 2009). However there have been further studies 
investigating the p38 MAPK cascade in this context. One report poses a role for p38 MAPK 
in TCDD-activated AhR-mediated transcription of target genes (Shibazaki et al. 2004). On 
the other hand Tan et al reported that not p38 but rather ERK and JNK MAP kinases are 
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important for AhR activation (Tan et al. 2002). These controversial results suggest a 
specialized AhR function in each cell type also depending on the basic expression level of 
involved signaling proteins and susceptibility to signaling cascades.  
In addition to this we show that NiSO4 activation of LCs leads to the nuclear translocation of 
AhR. NiSO4 signaling is known to activate p38 MAPK (Miyazawa et al. 2008) therefore we 
speculate that p38 MAPK might play an important role in AhR activation. In our studies we 
analyzed the signaling events in PGN induced LC maturation by investigating AhR activation. 
We applied multiple signaling cascade inhibitors targeting p38 MAPK signaling (SB203580), 
β-catenin/Wnt signaling (SB216763), NFκB (RelA) signaling (SN-50) and JNK signaling 
(SP600125). We have observed that p38 MAPK inhibition does not completely inhibit AhR 
activation although SB203580 inhibitor tends to partially suppress it. One possible reason for 
this phenomenon could be that p38MAPK has four different isoforms namely α, β, γ and δ. 
The SB203580 inhibitor only inhibits the α and β subunit. It could be that the other two 
isoforms are involved in AhR activation. Dong et al have already implicated c-Src kinase 
pp60Src in AhR signaling (Dong et al. 2011; Dong and Matsumura 2008). It is known that this 
kinase activates the p38δ MAPK isoform.  
A possible way of elucidating the question which p38 MAPK isoform is implicated in AhR 
activation would be to infect LCs with retroviral constructs expressing the various isoforms 
and repeat the experiment to monitor changes in AhR activation. Interestingly the JNK 
inhibitor showed the strongest inhibition of AhR nuclear translocation. It is important to 
mention that there are controversial reports in the literature suggesting the SP inhibitor to be 
an AhR ligand, either with agonistic (Dvorak et al. 2008) or antagonistic effects (Joiakim et al. 
2003). Our results would imply an antagonistic function. Nevertheless further experiments 
are needed to clarify the question whether AhR inhibition comes from an antagonistic 
function or really from JNK inhibition. As the SP600125 inhibitor only prevents the upstream 
MAPKK to phosphorylate JNK, the inhibition is not quite specific. So far there are no 
inhibitors on the market which directly affect JNK MAPK. In addition to this it has to be said 
that p38 and JNK signaling are only hardly distinguishable because they are interlinked at 
many steps. The only possibility to specifically investigate JNK function in AhR signaling 
would be JNK knockout mice. Nevertheless only single knock-out mice are viable but not the 
JNK1/2 double knockout mice.  
Apart from JNK, NFκB subunit RelA seems to have the opposite effect. RelA inhibition 
enhances AhR activation. There are no reports in the literature suggesting an AhR agonistic 
role for the NFκB SN-50 inhibitor. Therefore it is reasonable to hypothesize that RelA plays a 
regulatory role in the process of AhR activation induced by PGN. However, further 
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experiments are needed to elucidate the role of signaling cascades in AhR activation. 
Considering the fact that lots of inhibitors share chemical structures of AhR ligands the 
method of choice for further investigations on AhR signaling are knock-out mice of the 
respective signaling cascades.  
 
AhR interplay with the NFκB subunit RelB in NiSO4-induced LC maturation: Infection 
experiments with the pBMNp100ΔN construct in CD34+ derived HSC achieved good 
transduction rates. We could reach an infection rate of 80-90%. After 7 days of LC 
differentiation GFP positive cells made up about 40-60% of the culture. As we did not sort the 
cells to avoid maturation due to physical handling we have to keep in mind that the results 
we have obtained come from a mixed cell population of GFP negative and GFP positive 
cells. However, differentiation does not change to a great extent in the GFP positive cells as 
we have analyzed with FACS staining. Upon NiSO4 activation GFP positive and GFP 
negative LCs loose CD1a/Langerin double positive expression due to maturation processes. 
Although Jörgl et al. showed that constitutive RelB cytoplasmic sequestration induces a 
significant hyper-maturation of LCs we did not see this pronounced phenotype (Jorgl et al. 
2007). Maturation markers of LCs in our experiments tended to be only slightly up-regulated 
or were left unchanged. However primary data suggest that inactivated cells tend to be 
slightly pre-activated before the actual NiSO4 stimulation, although further donors are needed 
to ensure this phenotype. Furthermore we performed immunostaining to investigate AhR and 
RelB localization. We could show that only strongly transduced LCs with the pBMNp100ΔN 
construct really show a potent inhibition of nuclear RelB staining, whereas slightly or 
intermediate positive GFP cells still show nuclear RelB staining although the intensity was 
reduced in large measures.  
One main question was whether AhR still translocates to the nucleus when RelB is held in 
the cytoplasm. With the help of immunostainings for AhR of transduced LCs we could show 
that AhR still translocates to the nucleus independently of the cellular localization of RelB. 
Therefore we can rule out that AhR and RelB form a physically attached heterodimer in the 
cytoplasm which only then translocates to the nucleus. NFκB signaling works in a manner 
where subunits form hetero- or homodimers in the cytoplasm which then are transferred to 
the nucleus (Hayden and Ghosh 2012). It is interesting that the potential AhR/RelB signaling 
interference does not make use of this cytoplasmic dimer formation mechanism. Furthermore 
this implies that AhR and RelB are regulated and modulated separately and independently of 
each other and that their signals are integrated at a later signaling stage.  
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Another interesting point of our experiment was to investigate whether RelB inhibition has 
any effect on IL8 cytokine production and secretion because Vogel et al has already reported 
about a role of AhR/RelB heterodimers in IL8 production in breast cancer cell lines. They 
showed that the inhibition of either AhR or RelB led to a decrease of IL8 production (Vogel et 
al. 2011). We observed that RelB inhibition in our system has a very immediate positive 
effect on IL8 cytokine secretion after 3 hours of NiSO4 activation. At later time points this 
effect dampens. It would be interesting to investigate even earlier time points of NiSO4 
activation to get a better understanding of time kinetic characteristics of this reaction. These 
results are inconsistent to the findings of Vogel et al because they showed that TCDD 
activation of cells led to an AhR- and RelB-dependent induction of IL8 which was in turn 
decreased after AhR or RelB silencing (Vogel et al. 2011).  
We further analyzed the il8 mRNA production by quantitative realtime PCR. Primary data 
support the model of an immediate (3h) positive effect on the IL8 promoter which levels out 
at later time points. When we integrate the data of this experiment we can speculate that 
NiSO4 activated AhR translocates to the nucleus and primes the IL-8 promoter which leads to 
subsequent and immediate transcription of the gene. RelB seems to have a regulatory role in 
this process because its inhibition leads to a pronounced increase in IL8 production and 
secretion. Vogel et al introduced a new AhR/NFκB DNA recognition element which is present 
in the promoter of IL8. In line with this we could not detect any induction of the typical AhR 
XRE-mediated target Cyp1a1 gene (data not shown). But at the same time AhR/NFκB-target 
IL8 was strongly induced. Nevertheless we could not observe the strictly AhR and RelB 
dependent IL8 induction as the cells with inhibited RelB in fact showed an up-regulation of 
the IL8 production. Therefore we conclude that activated AhR alone is able to induce IL8 
production and that nuclear RelB binding to AhR modulates the transcription of IL8 by yet 
unknown mechanisms.  
Further investigation of the IL8 promoter in our NiSO4-activated and p100ΔN infected LC 
system is needed to elucidate mechanisms taking place at DNA level in the regulation of IL8 
production. This hypothesis is quite astonishing because AhR and RelB signaling integration 
at the level of DNA poses a regulatory and fast-responding platform for fine-tuning of gene 
expression as transcriptional response to various danger signals. CHIP analysis and mobility 
shift analysis in combination with time kinetic studies are suitable for this purpose. We 
suggest that the recruitment of histon modification enzymes such as HCATs happens in an 
AhR-dependent way and is regulated by the interplay of RelB signaling.  
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In addition to this it would be interesting to repeat the same experimental set up with an AhR 
inhibitor to see whether the ablation of IL8 production can be achieved. Investigation of IL8 
promoter regulation of AhR or RelB knockout mice bone marrow derived DCs would be 
another interesting experiment although we have to keep in mind that at this stage of 
complex transcriptional regulation multiple aspects shape the outcome and cannot easily be 
applied to other cell types or even other species as demonstrated above with the different 
results from our lab compared to the findings of Vogel et al in breast cancer cell lines.  
In conclusion we found that AhR translocates to the nucleus independently of RelB upon the 
stimulation of Langerhans cells with the chemical sensitizer NiSO4. Nevertheless the 
interplay between AhR and RelB is needed on the level of gene expression regulation on 
DNA to fine-tune the immediate transcriptional response to NiSO4.  
References 
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and cell lines, migration and protein interaction assays, WB 
and immunostainings 
Immunology diploma thesis 12 months. Lab of Prof. Herbert Strobl, Institute of 
Immunology, Medical university Vienna. Research: Role of 
AhR in Langerhans Cell Differentitaion and Maturation. 
Techniques: primary cell culture and cell lines, 
immunostainings on cells and skin sections, WB, retroviral 
infections, qPCR, cloning, FACS 
 
Techniques 
Western Blot, FACS, biochemical protein interaction assays, immunfluorescent analysis (cells 
and tissue) with confocal or normal microscopic analysis and life imaging, real-time PCR, 
cloning, cell culture of primary cells and cell lines, cell isolations from mouse and human 
samples, retroviral gene transduction.  
 
Language and computer skills 
Computer knowledge 
 
Windows and Mac operating system, Microsoft Office, FlowJo, 
Endnote, Graphpad Prism4, Adobe Illustrator and Photoshop, 
ImageJ, Zeiss ZEN  
Languages German: 
English: 
French: 
Mother tongue 
fluent in speaking and writing 
basic knowledge 
Language courses  England (Eastbourne, Bexhill),  
Malta (St. Julian),  
France (Paris, Giverny),  
USA (New York, Connecticut) 
First Certificate in English (2004) 
 
Hobbies 
Playing the piano, hiking, skiing, yoga, gardening 
 
